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ABSTRACT 
 
THE PYRETHROID DELTAMETHRIN WHICH CAUSES CHOREOATHETOSIS 
WITH SALIVATION (CS-SYNDROME) ENHANCES CALCIUM ION INFLUX VIA 
PHOSPHORYLATED CAV2.2 EXPRESSED IN XENOPUS LAEVIS OOCYTES 
 
FEBRUARY 2012 
 
ANNA-MARIA F. ALVES 
 
B.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor John M. Clark 
 
 
 
Pyrethroids are insecticides used since the 1970s.  They are favored for their low 
mammalian toxicity, improved environmental stability and insecticidal potency. Voltage-
gated sodium channels (VGSCs) are a known target but in vitro evidence indicates that 
voltage-gated calcium channels (VGCCs) are also targets. Site-directed mutagenesis of 
CaV2.2 (N-type), altering threonine 422 to glutamate (T422E), produces a mutant channel 
that acts as if permanently phosphorylated. Deltamethrin increases peak current of T422E 
CaV2.2 compared to its antagonistic action on wild type CaV2.2 when expressed in 
Xenopus oocytes.  Phosphorylation of wild type CaV2.2 is evoked by the phorbol ester 
PMA by activating endogenous protein kinase C (PKC) in oocytes.  Under steady-state 
conditions, deltamethrin increases transient peak current and slows deactivation kinetics 
of the PKC phosphorylated channel thereby increasing Ca
2+
 influx and neurotransmitter 
release. Conversely, deltamethrin treatment resulted in no effect on the deactivation 
kinetics of the unphosphorylated or T422E channels. Under voltage-dependent 
conditions, deltamethrin enhances peak current, and causes a hyperpolarizing shift in 
vii 
 
activation midpoint potential of the PKC phosphorylated channel which is consistent with 
enhanced Ca
2+
 influx. The hyperpolarizing shift of activation midpoint potential was not 
observed when deltamethrin was applied to the T422E mutant channels indicating that 
the other phosphorylation sites on CaV2.2 may be playing a role in the differential effects 
observed in the action of deltamethrin on the unphosphorylated channel, the T422E 
mutant and the PMA-activated PKC phosphorylation channel.
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
1.1 Pyrethroid Insecticides 
 
Pyrethroids are a class of synthetic insecticides used widely since the 1970s both 
in agriculture and urban environments. They are derived from the naturally-occurring 
insecticide pyrethrum, which is isolated from the flower heads of the chrysanthemum 
flower Chrysanthemum cinerariaefolium. Pyrethrum is highly labile due to its instability 
in sunlight and water caused by spontaneous cleavage of the central ester bond by 
photolysis and hydrolysis, respectively (Soderlund et al., 2002; Hossain et al., 2004). It is 
a mixture of six pyrethrin esters: pyrethrin I (Fig. 1) and II, cinerin I and II, and jasmolin 
I and II. Pyrethroids (synthetic pyrethrins) were developed to meet the need for potent 
insecticides with low mammalian toxicity but without the drawbacks of environmental 
instability, which limited the effectiveness of pyrethrum in crop protection and vector 
control (Soderlund et al., 2002). Among the pyrethroids, there is no specific substructure, 
reactive entity, or molecular moiety that can be identified as the common toxophore 
conferring pyrethroid-like insecticidal activity. Instead, toxicity results from the goodness 
of fit of the entire molecule at its site of action (Soderlund et al., 2002).   
Pyrethroids target the voltage-gated sodium channels (VGSC) of insect pests as 
well as those of mammals, although mammalian VGSC vary in their biophysical and 
pharmacological properties from the insect channel. These differences result in different 
sensitivities of the various mammalian VGSC to pyrethroids (Soderlund et al., 2002). To 
date, the binding site of pyrethroids to VGSCs has yet to be elucidated. 
  2 
 The voltage-gated calcium channels (VGCC) and voltage-gated chloride channels 
(VGClC) are also pyrethroid targets and almost assuredly contribute to the overall 
neurotoxicity of the pyrethroids (Soderlund et al., 2002). A subset of α-cyano containing 
pyrethroids increased neurotransmitter release in the mammalian brain under 
depolarizing conditions. This effect is blocked by -conotoxin GVIA, a specific blocker 
of N-type VGCC, thereby implicating this subset of VGCC. The exact binding site on 
these channels has likewise yet to be elucidated (Brooks and Clark, 1987; Clark and 
Brooks, 1989; Soderlund and Lee, 2001; Hossain et al., 2004; Shafer and Meyer, 2004).   
 
  
 
1.2 Tremor (T-) and Choreoathetosis with Salivation (CS-) Syndromes 
Based on their structure and generally on their ability to produce either a tremor 
(T) or a choreoathetosis with salivation (CS) intoxication syndrome, pyrethroids have 
been classified into two groups (Soderlund et al., 2002). For the most part, Type I (non α-
Figure 1.  
 
 . The chemical structure of pyrethrin I, the most toxic ester of 
pyrethrum.  This structure is the basis for all pyrethroids (reproduced 
from Soderlund et al., 2002) (Soderlund et al., 2002). 
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cyano) pyrethroids elicit the T-syndrome and Type II (α-cyano) pyrethroids cause the CS-
syndrome of intoxication in mammals. T-syndrome symptoms include hypersensitivity, 
stimulus-induced bouts of general tremors, convulsive twitching, coma and death. CS-
syndrome symptoms include salivation, jerking leg movements, progressive writhing 
convulsions and death (Soderlund et al., 2002). Using a functional observational battery 
(FOB), bifenthrin, tefluthrin, β-cyfluthrin and λ-cyhalothrin, which had been previously 
uncategorized, were placed within the T/CS-syndrome system (Choi and Soderlund, 
2006; Weiner et al., 2009). Based on FOB data, two functional groups were proposed. 
Group 1 (T-syndrome) includes pyrethrins, resmethrin, permethrin, S-bioallethrin, 
bifenthrin, and tefluthrin. Group 2 (CS-syndrome) includes cypermethrin, deltamethrin, 
esfenvalerate, β-cyfluthrin and λ-cyhalothrin (Weiner et al., 2009). By exhibiting features 
of both groups, fenpropathrin, an α-cyano pyrethroid which had been previously 
described as causing a mixture of T- and CS-syndrome symptomologies and therefore not 
definitely a member of either class, remains unclassified (Breckenridge et al., 2009; 
Weiner et al., 2009).  
 
1.3 Pyrethroid Neurotoxicity 
The differences between how T- and CS-syndrome pyrethroids cause mammalian 
neurotoxicity apparently lay in their three-dimensional chemistry. The absence (Type I) 
or presence (Type II) of an α-cyano group in the 3-phenoxybenzyl alcohol moiety 
provides one of the key differences between the two types of pyrethroid structures. The 
presence of the α-cyano moiety provides Type II pyrethroids with a much greater level of 
insecticidal potency than their non α-cyano Type I counterparts, while maintaining the 
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same level of photostability (Soderlund et al., 2002). Type II pyrethroids are also less 
sensitive to ester bond hydrolysis (Brooks and Clark, 1987; Hossain et al., 2004).   
Previous studies have shown that Type I pyrethroids that produce the T-syndrome 
and Type II pyrethroids that cause the CS-syndrome cause differential effects on the 
release of acetylcholine (ACh) from both whole brain and cerebellum of rats (Aldridge et 
al., 1978). The study compared the effects of cismethrin (a Type I pyrethroid that causes 
T-syndrome) with those of deltamethrin (a Type II that causes CS-syndrome) and found 
that only deltamethrin caused significantly more ACh release compared to cismethrin. In 
another study, freely moving rats were dosed with allethrin (a Type I pyrethroid that 
causes T-syndrome) and deltamethrin and λ-cyhalothrin (Type II pyrethroids that cause 
CS-syndrome) (Hossain et al., 2004). In this study, allethrin had a dose-dependent effect 
on ACh efflux. Low doses caused an increase in ACh efflux whereas high doses caused a 
decrease.  Deltamethrin and λ-cyhalothrin had opposite results from one another: 
deltamethrin caused a dose-dependent increase in ACh release and λ-cyhalothrin caused a 
dose-dependent decrease. The differences apparent in the amount of neurotransmitter 
release in the presence of allethrin versus deltamethrin support the contention that some 
Type I and Type II pyrethroids may have different sites of action.  The differences 
between the actions of λ-cyhalothrin and deltamethrin on ACh release despite both being 
Type II pyrethroids may, in part, be due to the differences in their three-dimensional 
configurations. β-cyfluthrin and λ-cyhalothrin, both close structural analogs of 
deltamethrin, prolongs Na
+
 channel activation and deactivation kinetics beyond that of 
deltamethrin (Choi and Soderlund, 2006). Together with the FOB data, the prolongation 
of channel kinetics by β-cyfluthrin and λ-cyhalothrin, places the two pyrethroids within 
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the CS-syndrome class (Weiner et al., 2009).  
The aquatic ciliate Paramecium tetraurelia has been shown to be one of the most 
sensitive organisms to pyrethroids, especially deltamethrin (Clark et al., 1995), despite 
their lack of VGSCs, long considered a major pyrethroid target (Symington et al., 1999b). 
Electrophysiological experiments showed that deltamethrin was toxic to P. tetraurelia 
under depolarizing conditions because they caused a significant increase in Ca
2+
 influx 
via their voltage-gated calcium channel, which control cilia motor function. When 
exposed to Type-II pyrethroids, P. tetraurelia exhibit increased backwards swimming 
behavior, which is controlled explicitly by increased Ca
2+
 influx via VGCCs (Symington 
et al., 1999a; Symington et al., 1999b). Pawn mutants, which lack VGCCs, were 
unaffected by deltamethrin and wild type cells were unaffected by the inactive 1S 
enantiomer of deltamethrin. Lastly, deciliated paramecia are no longer sensitive to the 
toxic action of deltamethrin. In summary, these biochemical and behavioral studies have 
shown that: 1) there is a difference in the action of pyrethroids based on the presence or 
absence of an α-cyano group, and 2) in addition to VGSCs, VGCCs are also pyrethroid 
targets.   
 
1.4 Structure-Activity Relationships 
The structure-activity relationship (SAR) for pyrethroids is based on the physical 
properties and three-dimensional configuration of the entire molecule. Thus, the activity 
of a pyrethroid is based upon how well the entire molecule fits at the site of action and 
there exists a wide range of structures that satisfy this requirement (Elliott et al., 1974; 
Soderlund et al., 2002).   
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The stereospecificity at the C1 carbon of the cyclopropane ring of the acid moiety 
is a major SAR that confers insecticidal action. Pyrethroids that have the R configuration 
at C1 (1R) have high insecticidal activity whereas pyrethroids in the S configuration (1S) 
have no insecticidal activity despite being chemically identical to the 1R enantiomer 
(Elliott et al., 1974). For fenvalerate, which does not have a cyclopropane in its acid 
moiety, a S configuration around the C2 carbon of the 3-methyl butyrate moiety, which 
mimics the 1R configuration of cyclopropane-containing pyrethroids, confers insecticidal 
activity whereas the R configuration is not insecticidal (Soderlund et al., 2002).   
 
1.5 Voltage-gated Ion Channels 
Members of the voltage-gated ion channel family include sodium (Na
+
), 
potassium   (K
+
), chloride (Cl
-
) and calcium (Ca
2+
) ion channels and are found in various 
tissues (e.g., skeletal muscle, pancreas, cochlea, kidney, liver and nerve) where they 
provide a number of regulatory functions. VGSCs and VGCCs share substantial 
structural homology between their pore-forming α-subunits (Catterall, 1997; Shafer and 
Meyer, 2004). When either channel is activated, there is an influx of extracellular cations 
via the “opened” channel, which is positioned in the plasma membrane, thereby 
depolarizing the membrane. The voltage-gated potassium channel (VGPC) assist in 
rectifying membrane potential after depolarization by transporting K
+
 ions out of the cell 
to counteract the increase of positive charge on the inside due to the influx of cations 
(Na
+
, Ca
2+
) through VGSCs and VGCCs (Martinez-Pinna et al., 2000). Ca
2+
-activated Cl
-
 
channels also assist in rectifying membrane potential by transporting Cl
-
 ions into the cell 
in response to the increase in intracellular Ca
2+ 
(Hartzell et al., 2005).    
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1.6 Structure and Function of VGSCs 
VGSCs play a central role in the initiation and propagation of action and 
generator potentials of electrically excitable cells, such as neurons (Yu and Catterall, 
2003). VGSCs are multimeric proteins made up of an ion conducting pore (α-subunit) 
and the two auxiliary β-subunits, β1 and β2.  VGSC α-subunits contain four internally 
homologous domains, each made up of six α-helical transmembrane segments. β subunits 
are membrane-bound subunits connected to α-subunits by disulfide bonds..  Co-
expression of β subunits with the α subunit increases the level of functional expression, 
causes a shift in the voltage-dependence of activation, and greatly accelerates channel 
inactivation (Isom et al., 1992; Isom et al., 1995).    
Voltage dependence of the VGSCs plays a central role in the initiation and 
propagation of action potentials in nerve axons and in the production of electrical 
impulses in other electrically excitable cells. There are three functional characteristics 
that are used to identify VGSCs electrophysiologically. The first functional characteristic 
of VGSCs is activation which occurs via the outward movement of the positive “gating” 
charges on the helical S4 transmembrane segment of each transmembrane domain in 
response to changes in the membrane electric field (going from positive to negative on 
the outside surface of the membrane during depolarization) (Hodgkin and Huxley, 1952; 
Armstrong, 1981; Catterall, 2000a; Catterall, 2000b). The VGSC S4 transmembrane 
segment contains a cylindrical α-helix of repeating motifs consisting of one positive 
followed by two negative amino acids. When the ion-conducting pore of the channel is 
closed, the negatively charged internal electric field of the channel pulls the positively 
  8 
charged amino acids of the S4 helix into the cell. In response to depolarization of the 
membrane, the S4 segment moves outward from the cell changing the conformation of 
the channel from a closed state to an open state thus allowing for the movement of ions 
through the ion conducting pore (Catterall, 2000b). The influx of Na
+
 ions through the 
pore formed by the activated α-subunit further depolarizes the membrane and initiates the 
rising phase of the action potential. The conformational change of VGSC from a closed to 
an open state (activation) as the result of the S4 segments response to membrane 
depolarization occurs within a few milliseconds. The influx of Na
+
 ions through the open 
channel into the cell is characterized by a measured transient peak current.   
The second functional attribute is channel inactivation, which occurs under 
steady-state depolarization in response to channel activation, is characterized by the 
decay of “transient peak current”. Under steady-state depolarization, VGSC inactivates 
when the inactivation gate, the intracellular III-IV transmembrane loop of the α-subunit, 
moves to block the ion-conducting pore by binding to a receptor on the intracellular 
mouth of the pore (Armstrong, 1981; Kellenberger et al., 1996; Catterall, 2000b; Kass, 
2004). In sodium channels, inactivation is biphasic with the initial phase ηfast and the 
slower secondary phase ηslow  and is measured as “late current” (Tan and Soderlund, 
2009). Fast inactivation (ηfast) is regulated by the inactivation gate and is coupled to 
channel activation whereas slow inactivation (ηslow) is voltage-dependent (Kass, 2004).  
The third functional attribute is deactivation. The current that occurs after the 
removal of steady state membrane depolarization (repolarization) is termed “tail current” 
and is a measure of deactivation.   
In mammals, multiple VGSC isoforms exist that are encoded by a family of 
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homologous genes. Each isoform varies in its sensitivity to pyrethroids, both within and 
between the α- and non-cyano structural classes, which make the characterization of 
mammalian VGSCs complicated (Goldin et al., 2000; Soderlund et al., 2002; Yu and 
Catterall, 2003). The complete VGSC sequences for mammalian isoforms are designated 
as NaV1.1-NaV1.9 and each has been functionally characterized as encoding a voltage-
gated ion channel (Goldin et al., 2000). The expression patterns of the different VGSC 
isoforms are tissue dependent and developmentally regulated (Choi and Soderlund, 
2006). VGSCs are expressed in cardiac muscles, skeletal muscles and different 
anatomical regions of the central and peripheral nervous systems (Yu and Catterall, 2003) 
and exist in several states of alertness: closed resting state, open activated state, inactive 
open state, and inactive closed state (Rossie, 1999).   
 
1.7 Neuropharmacology of Mammalian VGSC 
VGSCs located in the rat dorsal root ganglion neurons can be formally divided 
into three groups. VGSCs whose currents are blocked by the neurotoxin tetrodotoxin 
(TTX) are TTX-sensitive (TTX-S), VGSCs whose currents are not blocked by TTX 
(TTX-resistant; TTX-R) and VGSCs whose currents are partially sensitive to TTX (TTX-
partially sensitive; TTX-PS) (Roy and Narahashi, 1992; Ginsburg and Narahashi, 1993; 
Ogata and Tatebayashi, 1993; Choi and Soderlund, 2006). Analysis of VGSC isoforms 
determined that carriers of TTX-R currents are very sensitive to pyrethroids and had 
much faster activation and inactivation rates than VGSC carriers of TTX-S currents 
(Ginsburg and Narahashi, 1993; Ogata and Tatebayashi, 1993). NaV1.8, the principle 
carrier of TTX-R current is located in the small diameter of the rat dorsal root ganglion 
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neuron (DRG), which is part of the peripheral nervous system (Akopian et al., 1996).   
 
1.8 Pyrethroid Neurotoxicity to Mammalian VGSCs 
Pyrethroids alter the normal function of VGSC by acting as channel agonists. 
Type I pyrethroids (e.g. allethrin, permethrin, tefluthrin, bifenthrin and cismethrin) have 
been shown to slow activation and inactivation kinetics of VGSC moderately while 
deactivation kinetics (tail current) decayed rapidly. On the other hand, Type II pyrethroids 
(e.g., deltamethrin, cypermethrin) slow activation and inactivation kinetics more than 
Type I pyrethroids and significantly slow deactivation, leading to extensive prolongation 
in the Na
+
 tail current.  Fenvalerate and fenpropathrin, both α-cyano pyrethroids, changed 
VGSC kinetics to a degree that was intermediate between the Type I and Type II 
pyrethroids. Although fenvalerate has been classified as a Type II pyrethroid based on 
other criteria and fenpropathrin has been characterized as a Type II pyrethroid structurally 
but is intermediate in its action in a FOB study (Weiner et al., 2009). Fenvalerate and 
fenpropathrin slow activation and inactivation kinetics much like Type II pyrethroids, but 
tail currents rapidly decay like Type I pyrethroids. Cyhalothrin and cyfluthrin (α-cyano) 
also cause extremely slow deactivation kinetics allowing pronounced tail current. In fact, 
cyhalothrin effect was greater than that of deltamethrin, which makes it an extreme 
example of a Type II pyrethroid that produces the CS-syndrome. The effect of cyfluthrin 
on tail current was also greater than deltamethrin, but was not as significant as that of 
cyhalothrin (Choi and Soderlund, 2006).   
VGSCs mediate the transient Na
+
 permeability of the cell membrane that is 
associated with the production of rising phase of the action potential in vertebrate and 
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invertebrate nerves and in vertebrate skeletal and cardiac muscles. Type I pyrethroids 
increase the rate of VGSC activation by causing a hyperpolarizing shift of the membrane 
potential at which VGSC activate (Shafer et al., 2005), moderately slow channel 
inactivation and cause rapidly decaying deactivation kinetics (Choi and Soderlund, 2006). 
These effects on VGSC kinetics by Type I pyrethroids produce transient depolarizing 
after potentials and result in repetitive firing of action potentials (repetitive discharges), 
which are the cause of the T-syndrome (Shafer et al., 2005; Choi and Soderlund, 2006; 
Ray and Fry, 2006). Type II pyrethroids in general slow the rate of channel activation and 
inactivation but result in persistent tail currents. This prolonged opening of the channel 
allows excess Na
+
 ions to enter the nerve resulting in rapid and substantial membrane 
depolarization to the point that the generation of action potentials is no longer possible, a 
condition called conduction block (Soderlund and Bloomquist, 1989; Soderlund et al., 
2002; Hildebrand et al., 2004; Shafer and Meyer, 2004; Ray and Fry, 2006).   
 
1.9 Classification and Function of VGCCs 
VGSCs are not the only channels affected by pyrethroids.  VGCCs, which play a 
role in nerve cell excitability, calcium homeostasis, synaptic signaling and gene 
expression modulation, are also affected.  VGCC are heteromeric protein complexes 
made up of α1, β, α2δ, and sometimes λ subunits. There are as many as ten α1 subunit 
isoforms of VGCCs (Catterall et al., 2003). Each forms the ion conducting pore of the 
channel and contains major determinants for functional and pharmacological properties 
of VGCCs. All α1 subunits have four repeating domains, each consisting of six 
transmembrane α helical segments (S). There is a membrane associated loop between S5 
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and S6 in each domain. The S4 segment of each homologous domain serves as the 
voltage sensor for activation (Catterall, 2000a). There are four the β subunit isoforms and 
unlike the α1-subunit, all are entirely cytoplasmic. The β subunit modulates functional 
characteristics and membrane expression of the α- subunits (Hanlon and Wallace, 2002; 
Shafer and Meyer, 2004).   
There are five types of VGCC that exist and they are classified based upon their 
biophysical, electrophysiological and pharmacological properties (Table 1). VGCC 
channel types are functionally characterized into two groups: those that activate under 
large depolarizations (high voltage activated; HVA) and those that activate under small 
depolarizations (low voltage activated; LVA). HVA channels are further divided based on 
the basis of tissue distribution, biophysical and pharmacological properties into two 
different gene families; CaV1.2 (L-Type), CaV2.1 (P/Q-type), CaV2.2 (N-Type), and 
CaV2.3 (R- type) channels. CaV3.1 (T-type) channels are the only form of LVA channels. 
The Cav2 channels are responsible for the release of neurotransmitters in the neocortex, 
hippocampus, cerebellum, neuromuscular junction and the peripheral autonomic effectors   
(Soderlund et al., 2002; Catterall et al., 2003).Cav1 channels, under certain conditions or 
at certain synapses, will also mediate neurotransmitter release (Xu et al., 1998).   VGCC 
expression is developmentally regulated. Cav2 channels express early during the 
development of the nervous system and are most critical in cerebellar granule migration, 
gene activation and neurotransmitter release. CaV2.2 from rat brain is the most important 
of the VGCCs in neurotransmitter release and in pain transmission pathways (Drean et 
al., 1995; Finkbeiner and Greenberg, 1998; Vance et al., 1998; Shafer and Meyer, 2004).   
VGCCs are further defined based on the pharmacological profile and functional 
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characteristics of each of their α1 subunits. The CaV1 subfamily conducts L-type currents 
of the 1S, C, D and F α1 subunits. The CaV2 family conducts N (α1B), P/Q (α1A) and R-
type (α1E) Ca
2+
 currents. T-type calcium currents are conducted by the CaV3 family of α 
subunits (α1G, α1H and α11) (Perez-Reyes, 2003; Shafer and Meyer, 2004). Of these, the 
focus of our investigation will be on the CaV2.2, or N-type channel, which is localized at 
low density dendrites and high density nerve terminals of many classes of central 
neurons, and is the most important VGCC regulating Ca
2+
 dependent neurotransmitter 
release following depolarization of presynaptic nerve terminals (Catterall, 1997).   
 
1.10 Effects of Pyrethroids on VGCCs 
In general, pyrethroids decreased transient peak current of VGSC, prolonged 
channel inactivation under depolarizing conditions, and slow VGSC closure after 
repolarization (deactivation) (Narahashi, 1992). To assess what effect pyrethroids have on 
mammals, freely moving rats were dosed with cismethrin (Type I pyrethroid that 
produces the T-syndrome) and deltamethrin (Type II pyrethroid that produces the CS-
syndrome) (Aldridge et al., 1978). Analysis of neurotransmitter content of the 
hippocampus and the whole brain after dosing revealed that deltamethrin significantly 
decreased the amount of ACh in each brain region whereas cismethrin did not. Rats 
similarly treated with DDT in the same study had no significant increase of ACh release 
from either of the brain regions studied compared to the control (Aldridge et al., 1978). 
Deltamethrin administered to freely moving rats caused a dose-dependent increase in the 
release of ACh from the hippocampus (Hossain et al., 2004).  
Together, these studies showed that the CS-syndrome displayed with the dosing of 
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most Type II pyrethroids is likely due to target sites other than VGSCs. A hyperpolarizing 
shift in membrane potential of VGSCs due to the presence of Type I pyrethroids and 
DDT slow channel inactivation and increase late current causing depolarizing after 
potentials (DAP). DAP cause spontaneous firing of action potentials and long trains of 
repetitive discharges which are related to the tremors produced by T-type pyrethroids.  
Type II pyrethroids cause use-dependent conduction block of the action potential and a 
depolarizing shift in the resting membrane potential by prolonging deactivation kinetics 
and increasing tail currents (Narahashi and Yamasaki, 1960; Soderlund and Bloomquist, 
1989; Narahashi, 1992).  
The studies in which rats are dosed with Type II pyrethroids, such as deltamethrin, 
showed that there was significant neurotransmitter release, a process which is not 
controlled by VGSCs, and furthermore these studies showed that Type II poisoning 
caused CS-syndrome. These studies also showed that Type I pyrethroids, like DDT, 
caused tremors and other symptoms classified under T-syndrome poisoning. It follows 
from these studies, therefore, that there are alternative targets for Type II pyrethroids, in 
particular VGCCs which do control neurotransmitter release. Comparatively, decreased 
peak current and prolongation of activation and inactivation kinetics were observed in 
deltamethrin-treated N-type VGCC (CaV2.2), but deactivation kinetics remained 
unmodified (Symington and Clark, 2005). In rabbit striatal slices, cypermethrin, 
deltamethrin, and fenvalerate evoked neurotransmitter release 3- to 5-fold above the 
spontaneous release. Furthermore, fenvalerate also elicited a stereospecific and 
concentration-dependent release of neurotransmitters from the rabbit striatal slices (Eells 
and Dubocovich, 1988). In mouse spermatogenic cells, fenvalerate reduced T-type Ca
2+
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current and caused a hyperpolarizing shift in the current-voltage relationship of the 
channel as well as the steady-state inactivation of the channel (Xiao et al., 2006).   
Pyrethroids also block distinct classes of VGCCs in a variety of non-neuronal 
mammalian systems. Two distinct VGCC types from mouse neuroblastoma cells (N1E-
115), a transient (T-type) and a long lasting (L-type) Ca
2+
 current, were examined 
(Narahashi et al., 1987). Tetramethrin, a T-syndrome pyrethroid, preferentially blocked T-
type calcium current by 75% but only 30% of the L-type current (Yoshii, 1985). More 
recent electrophysiological studies using CaV3.1 (T-type), CaV1.2 (L-type), and CaV2.1 
(P/Q-type) expressed in non-neuronal HEK cells indicated that all three current types 
were effectively blocked by allethrin (a Type I, T-syndrome-producing pyrethroid). The 
block caused an increase in the rate of channel inactivation during steady-state 
depolarization as well as a hyperpolarizing shift in the voltage-dependent inactivation 
(Hildebrand et al., 2004). The contributions of these effects are consistent with the 
channel block observed. 
The increase in the rate of inactivation and the insignificant change in tail current 
of CaV3.1, CaV1.2 and CaV2.1 in the presence of allethrin is inconsistent with earlier 
studies that have shown pyrethroids to delay inactivation and slow the deactivation of tail 
currents (Vais et al., 2000; Soderlund et al., 2002; Wang and Wang, 2003; Hildebrand et 
al., 2004)   
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Table 1. Voltage-gated calcium channel (VGCC) subunit compositions and functions 
(adapted from Catterall 2003 (Catterall et al., 2003)). 
Ca
2+
 Channels 
Ca
2+
 Current 
type 
Primary 
Localizations 
Cellular Functions 
CaV1.1 L Skeletal muscle Excitation-contraction 
coupling 
Calcium homeostasis 
Gene regulation 
CaV1.2 L Cardiac muscle 
Endocrine cells 
Neurons 
Excitation-contraction 
coupling 
Hormone secretion 
Gene regulation 
CaV1.3 L Endocrine cells 
Neurons 
Hormone secretion 
Gene regulation 
CaV1.4 L Retina Tonic neurotransmitter 
release 
CaV2.1 P/Q Nerve terminals 
Dendrites 
Neurotransmitter release 
Dendritic Ca
2+
 transients 
CaV2.2 N Nerve terminals 
Dendrites 
Neurotransmitter release 
Dendritic Ca
2+
 transients 
CaV2.3 R Cell bodies 
Dendrites 
Nerve terminals 
Ca
2+
 -dependent action 
potentials 
Neurotransmitter release 
Repetitive firing 
CaV3.1 T Cardiac muscle 
Skeletal muscle 
Neurons 
Repetitive firing 
CaV3.2 T Cardiac muscle 
Neurons 
Repetitive firing 
CaV3.3 T Neurons Repetitive firing 
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al., 2004). Comparatively, deltamethrin has been shown to partially block CaV2.2 (N-
type) currents heterologously expressed in Xenopus oocytes, which was accompanied by 
a slight hyperpolarizing shift in the voltage dependence of activation and a slowing of 
channel activation and inactivation (Symington and Clark, 2005).  Peak, end, and tail 
currents of L-type (CaV1) Ca
2+
 channels expressed in PC12 cells significantly increased 
in the presence of allethrin and voltage-dependent peak current was shifted to more 
hyperpolarizing potentials(Neal et al., 2010). Neal et al (2010) also showed allethrin 
caused a shift in voltage-dependent activation and inactivation kinetics. The differential 
effects of allethrin on VGCCs indicate that Type I pyrethroids target some VGCC 
subtypes, but not others, in addition to targeting VGSCs. The differential effects may be 
due to the phosphorylation states of the channels or other forms of post-translational 
modifications. Type II pyrethroids certainly have an effect on VGCCs but again, the 
degree to which they have an effect appears to be based on the post-translational 
modification state of the channel. 
 
1.11 Role of CaV2.2 in Neurotransmitter Release 
CaV2.2 is expressed in presynaptic nerve terminals and is the predominant 
channel that regulates calcium-dependent, vesicle-mediated neurotransmitter release 
during membrane depolarization. The treatment of  isolated presynaptic nerve terminals 
(synaptosomes) with deltamethrin causes an increase in neurotransmitter release as a 
result of Ca
2+
 influx via CaV2.2 (Augustine et al., 1987). Treatment of deltamethrin, a 
Type II/CS-syndrome pyrethroid, on CaV2.2 expressed in Xenopus oocytes resulted in a 
hyperpolarizing shift of the midpoint potential of activation, prolonged inactivation, and 
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decreased peak current. These effects were stereospecific and dose-dependent 
(Symington and Clark, 2005). Enhanced activation and prolonged inactivation kinetics of 
heterologously expressed CaV2.2 is consistent with increased neurotransmitter release 
observed from the treatment of synaptosomes with deltamethrin.  However, the inhibition 
of peak current may be inconsistent with the enhanced neurotransmitter released 
observed in treated synaptosomes (Symington and Clark, 2005). 
CaV2.2 exists either in a “willing” or a “reluctant” state. In the willing state, the 
channel undergoes rapid activation during depolarization to voltages within its 
physiological range. In the reluctant state, the channel undergoes slow activation at more 
positive voltages beyond its normal range of physiological membrane potential (Catterall, 
2000a). Channel conductance is regulated by two separate processes: activation and 
inactivation. Activation controls the time and voltage dependence required to open the 
channel after depolarization and inactivation measures the voltage and time dependence 
of channel closure during maintained depolarization (Catterall, 1997; Hanlon and 
Wallace, 2002). Deactivation is a third kinetic measurement that describes the time 
dependence of complete closure of channels that have activated but not inactivated after 
the removal of membrane depolarization (Kostyuk and Shirokov, 1989).   
Activation and inactivation kinetics can be modified by several proteins and 
through phosphorylation of the α-subunit by protein kinases. The Gβγ subunit of the 
heteromeric G-proteins and SNARE proteins can modify channel kinetics by direct 
binding to the transmembrane domains of the α1 subunit. Modulation by Gβγ causes a 
hyperpolarizing shift in voltage dependence and slows channel activation. 
Phosphorylation of the α1D channel at T422 or S425 (Fang et al., 2006) downstream of 
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where Gβγ interacts on the I-II intracellular loop or a strong depolarization can reverse the 
Gβγ inhibitory effect, resulting in increase Ca
2+
 currents. Unlike Gβγ, channel regulation 
by SNARE is Ca
2+
 dependent. Regulated by Ca
2+
, presynaptic CaV2.2 interacts directly 
with SNARE proteins and synaptotgamin. The interaction of SNARE proteins and 
CaV2.2 is required to dock synaptic vesicles near Ca
2+
 channels for fast and effective 
exocytosis and the interaction is considered crucial for synaptic transmission (Catterall, 
2000a). Locations on the synaptolemma where these processes co-organize are called 
“active release zones”. When both Gβγ and SNARE proteins become phosphorylated, 
they no longer have an effect on the channel. All members of the CaV2 subfamily are 
blocked by ω-conotoxin GVIA but CaV2.2 has the highest affinity for this channel 
blocker.  Inhibition of CaV2.2 by ω-conotoxin GVIA causes a hyperpolarizing shift in 
voltage dependence and a slowing of channel activation, which can be alleviated by a 
strong depolarization resulting in Ca
2+
 current facilitation (Catterall, 2000a).  
 
1.12 Differences between in vivo and in vitro Action of Deltamethrin on CaV2.2 
Assays involving isolated presynaptic nerve terminals (synaptosomes) treated 
with deltamethrin were analyzed for enhanced Ca
2+
 influx and neurotransmitter release. 
Deltamethrin caused a significant increase in Ca
2+
 influx and glutamate release from 
synaptosomes in a concentration-dependant and stereospecific manner. No decrease in 
Ca
2+
 influx was observed when synaptosomes pretreated with the VGSC blocker 
tetrodotoxin (TTX), showing that Ca
2+
 influx was not VGSC-dependent and that there are 
additional sites at which deltamethrin is acting (Symington and Clark, 2005). The 
increase in Ca
2+
 influx that was the result of deltamethrin treatment and the deltamethrin-
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enhanced release of glutamate were abolished when synaptosomes were pretreated with 
the N- and P/Q- type Ca
2+
 channel blocker ω-conotoxin MVIIC (Symington and Clark, 
2005).   
The N-type VGCC isolated from rat brain (CaV2.2) were heterologously 
expressed in Xenopus oocytes, a non-neuronal expression system, to determine the 
specific effects of deltamethrin on this channel. Deltamethrin stereospecifically reduced 
the Ba
2+
 peak current in a concentration dependent manner. Treatment of CaV2.2 with 
deltamethrin caused a hyperpolarizing shift in the voltage-dependent activation kinetics 
of the channel as well as prolonging inactivation gating characteristics. The 
hyperpolarizing shift in the voltage-dependent activation of CaV2.2 as well as the 
prolongation of the inactivation kinetics means that the channel is more sensitive to 
opening at lower potentials and stays open longer allowing for more Ba
2+
 ions to influx 
through the channel (Symington and Clark, 2005). 
 
1.13 Protein kinase C (PKC) 
Phosphorylation also plays an important role in the modulation of CaV2.2. 
Phosphorylation of CaV2.2 can reverse Gβγ inhibition and cause an up regulation of Ca
2+
 
currents via CaV2.2 expressed in intact neurons and transient expression systems. Protein 
kinase C (PKC) is responsible for the phosphorylation of CaV2.2 and the subsequent 
antagonism of G protein-mediated inhibition of the channel. This interaction between 
PKC and Gβγ is termed “cross talk” (Swartz, 1993; Zamponi et al., 1997; Cooper et al., 
2000; Doering et al., 2004).   
PKC takes part in cellular responses to various agonists including hormones, 
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neurotransmitters and some growth factors. Agonist-induced hydrolysis of inositol 
phospholipids by phospholipase C produces IP3, which releases Ca
2+
 stores from 
endoplasmic reticulum. Cytosolic free Ca
2+
 and membrane-bound diacylglycerol (DAG) 
react to activate PKC. Metabolically-stable, tumor-promoting phorbol esters, such as 
phorbol ester 12-myristrate, 13-acetate (PMA), mimic DAG activity in a Ca
2+
 
independent manner and are capable of activating PKC for longer periods of time than 
DAG and several doses of DAG are required to achieve the same effect as one dose of a 
phorbol ester (Nishizuka, 1992; Mosior and Newton, 1996; Newton, 2001). 
The protein kinase C (PKC) enzyme family consists of ten Ser/Thr 
phosphotransferases and is divided into three subfamilies: conventional (PKCα, PKCβ1, 
PKCβ2, PKCγ), novel (PKCδ, PKCζ, PKCε, PKCε) and atypical (PKCδ, PKCλ). Every 
PKC has a regulatory domain and a catalytic domain. Within their regulatory domains, 
conventional and novel PKCs contain two C1 domains and a C2 domain, both of which 
are targets for different second messengers. Atypical PKCs only contain a single C1 
domain. Common to all three subfamilies of PKC are domains C3 and C4 which make up 
the catalytic domain of PKC. Phosphorylation of PKC occurs at threonine 567 on the 
activation loop by phosphoinositide-dependent kinase (PDK-1) quickly followed by 
phosphorylation of threonine 711 on the turn motif and serine 729 in the hydrophobic 
region by autophosphorylation. Phosphorylation and the binding of cofactors induce long 
range conformational changes that regulate the domain interactions. 
PKC exists under acute structural and spatial regulation. Its state of 
phosphorylation, conformation and sub-cellular location must each be tightly controlled 
for PKC to function properly. The catalytic domain comprises a conserved kinase core 
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containing the ATP-binding site, consensus phosphorylation sites, substrate binding and 
phototransfer sites (Newton, 2001; Corbalán-García and Gómez-Fernández, 2006). In 
order for PKC to become catalytically active, phosphorylation has to occur at three sites 
in the catalytic domain of the enzyme. Sites on the activation loop (Thr567), turn motif 
(Thr711), and hydrophobic motif (Ser729) of the PKC catalytic domain are 
phosphorylated via different mechanisms. The cofactors that regulate PKC conformation 
are phosphatidylserine (PS), DAG and Ca
2+
. Not all of the cofactors regulate all of the 
PKCs. Conventional PKCs are regulated by PS, DAG and Ca
2+
. Novel PKCs are 
regulated by PS and DAG. Atypical PKCs are regulated by just PS. Despite 
phosphorylation of its catalytic domain and its translocation to the membrane via binding 
of DAG and PS, PKC can still be held in an inactive state by the occupation of its kinase 
core by its pseudosubstrate (Newton, 2001). In order for unimpaired signaling of PKC to 
occur, its catalytic domain needs to be phosphorylated, PKC needs to translocate from the 
cytosol to the membrane via binding of its C1 and C2 domains to DAG and PS, 
respectively, and the allosterically regulating pseudosubstrate needs to be released from 
the kinase core.   
DAG, a product of phospholipase C (PLC) hydrolysis of phosphatidyl inositol-
biphosphate (PIP2), is a second messenger phospholipid that binds to the C1 region of 
PKC and in the process of activating the protein, sequesters it to the plasma membrane 
(Liu and Heckman, 1998). The effects of phorbol esters on PKC are slightly different 
from the effects of DAG although they operate by the same mechanism (Newton, 2001). 
Their biological effects differ for two reasons: 1) membrane recruitments and activation 
by DAG is short lived because DAG is rapidly metabolized whereas phorbol esters are 
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not, and 2), phorbol esters are two times more potent than DAG on a molar basis in 
recruiting PKC to membranes.   
Several different isozymes of PKC exist in neuronal channels and each has its 
own particular set of substrates. It has been shown that novel PKC, PKCε, is specific to 
phosphorylating CaV2.2 through the adaptor protein enigma homolog (ENH) (Newton, 
2001; Maeno-Hikichi et al., 2003), but in many cases, the presence of ENH is not 
required to phosphorylate the Ca
2+
 channel (Stea et al., 1995; García-Ferreiro et al., 2001; 
Maeno-Hikichi et al., 2003). PKCε has also been confirmed to be present in Xenopus 
oocytes although it remains inactive unless activated by PMA (Maeno-Hikichi et al., 
2003). 
 
1.14 Dephosphorylation by Protein Phosphatases 
Multiple families of Ser/Thr protein phosphatases (PP) have been identified in the 
brain and include PP1, PP2a, PP2b and PP2c. Just as individual kinases are capable of 
mediating unique cellular functions by adding phosphate groups to proteins, PPs are 
capable of removing phosphate groups from CaV2.2. However, much less is understood 
about which PP is responsible in regulating neuronal Ca
2+
 channel activity (Li et al., 
2005).   
It is yet to be determined which PP removes the phosphate group from T422 on 
CaV2.2. Of the five possible phosphorylation sites on the I-II and II-III intracellular loops 
of CaV2.2 for PKCε to interact with (Maeno-Hikichi et al., 2003; Fang et al., 2006), Li et 
al. (Li et al., 2005) have demonstrated that the protein phosphatase PP2cα was more 
effective in dephosphorylating the II-III intracellular loop than its PP counterparts. As for 
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the I-II intracellular loop, which includes T422, none of the PPs examined by Li et al. 
were effective in their individual ability to dephosphorylate the region, but when 
combined, the dephosphorylation rate of the I-II loop increased.  
 
1.15 Effect of PMA-activated PKC modulation on Wild Type CaV2.2 
PKC is a regulatory enzyme that phosphorylates serine and threonine residues.  
PMA up regulates PKC phosphorylation, which results in the addition of phosphate 
groups to residues Thr422 (T422), Ser425 (S425), Ser1757 (S1757), Ser2108 (S2108) 
and Ser2132 (S2132) (Stea et al., 1995; Fang et al., 2006). Phosphorylation of CaV2.2 
removes G-protein mediated inhibition via the Gβγ subunit, which allows increased Ca
2+
 
influx and a subsequent increase in neurotransmitter release (Nichols et al., 1987; García-
Ferreiro et al., 2001). Stea  et al. (Stea et al., 1995) showed that within Xenopus oocytes, 
PMA-activated endogenous PKC phosphorylates heterologously expressed CaV2.2, 
which elicits a time-dependent increase in peak current. PMA enhancement of PKC 
activity in rat brain caused enhanced excitatory synaptic transmission (Swartz et al., 
1993), reduced suppression by metabotropic glutamate receptor (G-protein mediated) 
agonists (Barrett and Rittenhouse, 2000), enhanced whole cell current amplitude in 
sympathetic neurons (García-Ferreiro et al., 2001) and increased Ca
2+
-dependent 
neurotransmitter release from synaptosomes (Nichols et al., 1987; García-Ferreiro et al., 
2001). Thus, VSCCs are modulated by direct phosphorylation that alter channel 
sensitivities to changes in membrane potential or channel ability to undergo 
conformational changes from an open state to inactive or closed states (Rossie, 1999). 
Treatment of synaptosomes with phorbol esters stimulated endogenous PKC activity, 
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which resulted in enhanced Ca
2+
-dependent neurotransmitter release (Nichols et al., 
1987). These results are consistent with the contention that PKC phosphorylation changes 
VSCC sensitivity to membrane depolarization and causes an increase in Ca
2+ 
influx and 
neurotransmitter release.   
 
1.16 Mutant CaV2.2 
It has been shown that deltamethrin has an agonistic effect on Ca
2+ 
influx and 
neurotransmitter release in rat brain synaptosomes (Aldridge et al., 1978; Hossain et al., 
2004; Symington and Clark, 2005; Symington et al., 2007b). However, deltamethrin 
inhibits Ba
2+
 peak current when CaV2.2 is heterologously expressed in Xenopus oocytes 
(Symington and Clark, 2005). This difference in channel response to deltamethrin 
treatment, depending on the expression system, is believed to be due, in part, to the lack 
of active post-translational modifications in the non-neuronal oocytes versus active post-
translational modifying enzymes, such as protein kinases, within rat brain synaptosomes.   
The intracellular loop between domains I and II on the CaV2.2 α1 subunit is a 
highly regulated domain (the alpha-subunit interacting domain, AID), which contains 
T422 and the overlapping binding sites for PKC, Gβγ and the VGCC β subunit (Cooper et 
al., 2000). A specific phosphorylation of CaV2.2 by PMA-activated PKC can be 
mimicked by an amino acid substitution in the PKC regulatory site within the I-II 
intracellular domain. Conversion of threonine 422 to glutamic acid (T422E) results in a 
channel that functions as if it were permanently phosphorylated since glutamic acid is 
negatively charged at physiological pH. This mutation produces a CaV2.2 phosphoform 
that mimics the effect of PMA up-regulation and is no longer sensitive to Gβγ inhibition 
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(Hamid et al., 1999; Cooper et al., 2000; Symington et al., 2007a). 
Using this approach, it has been shown that the T422E mutation alters the action 
of deltamethrin on CaV2.2 expressed in Xenopus oocytes (Symington et al., 2007a).  
Deltamethrin significantly enhanced peak current via the T422E channel compared to the 
wild type, the solvent-treated control and a T422A (permanently unphosphorylated 
mutant) channel. This effect was stereospecific and concentration dependent. Additional 
effects of deltamethrin on T422E included a more positive activation midpoint potential, 
a depolarizing shift in the voltage dependence of activation. However, no change in the 
activation or inactivation tau values was observed as seen previously on the wild type 
channel. As demonstrated in the mutant T422E experiments, CaV2.2 is clearly modified 
by deltamethrin but the resulting perturbation is highly dependent upon the 
phosphorylation state of T422.   
 
1.17 The Effect of PMA-activated PKC Phosphorylation on Wild Type CaV2.2 is 
enhanced by Deltamethrin Treatment  
Post-translational modifications of CaV2.2 have been suggested to be the cause of 
the differences between the agonistic effect deltamethrin elicited in rat brain 
synaptosomes versus its antagonistic effect on the Ba
2+
 peak current via heterologously 
expressed CaV2.2 in Xenopus oocytes. The increase in peak current following 
deltamethrin treatment of T422E is highly suggestive that the phosphorylation state of 
CaV2.2 determines its response to deltamethrin (Symington et al., 2007a).    
Using PMA to up regulate PKC activity in Xenopus oocytes, CaV2.2 is readily 
phosphorylated, although phosphorylation of the channel is nonspecific (Cooper et al., 
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2000).  It is our contention that deltamethrin enhances Ca
2+
 influx and subsequent 
neurotransmitter release only when acting upon a phosphorylated channel.  By activating 
PKC with PMA, we are able to nonspecifically phosphorylate CaV2.2, which was 
heterologously expressed in Xenopus oocytes, and enhance channel conductance. We 
expect that the addition of deltamethrin and other CS-syndrome pyrethroids will further 
enhance the conductance of phosphorylated CaV2.2 in a stereospecific manner. By 
analyzing peak current and channel kinetics, such as activation, inactivation, deactivation, 
we will investigate which channel properties are influenced by phosphorylation in the 
presence and absence of pyrethroids.  
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
2.1 Materials 
Technical grade deltamethrin ((S)-α-cyano-3-phenoxybenzyl (1R,3R)-3-(2,2-
dibromovinyl)-2,2-dimethylcyclopropanecarboxylate; isomeric composition: 95.0% (Z)-
(1R)-cis-)) was provided by Aventis CropScience (Dublin, NJ), a member of the 
Pyrethroid Working Group (PWG); a conglomerate of the major pyrethroid manufactures 
in the United States and United Kingdom and includes Valent USA Corp. (Montvale, CA) 
and Syngenta (Cheshire, UK), FMC (Philadelphia, PA), DuPont Agricultural Products 
(Newark, NJ), and Bayer Corp. (Kansas City, MO). Phorbol 12-myristate, 13-acetate 
(PMA; ≥99% pure) was purchased from Calbiochem (# 524400; La Jolla, CA). 4α-
phorbol 12-myristate, 13-acetate (4α-PMA; 98%) was purchased from Sigma-Aldrich (# 
79352; St. Louis, MO). An isomeric mixture of cypermethrin was provided by Shell Corp 
(Houston, TX).   Pyrethroid, PMA and 4α-PMA stocks were prepared in dimethyl 
sulfoxide (DMSO) and diluted with either DMSO or BaCl2 recording solution as 
required.  Chemical structures for pyrethroids and phorbol esters used in this study are 
included in Appendix A.   
 
2.2 Animals 
Female Xenopus laevis frogs (7.5-9 cm) were purchased from Nasco (Fort 
Atkinson, WI) and maintained on a 12:12 hr day and night light cycle in a 19 
o
C 
incubator. Animals were housed in plastic bins (61.54 cm x 41.45 cm x 32.47 cm) in 5 
gallons of dechlorinated water at 5 females per bin. Animal procedures were conducted in 
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accordance with the Institutional Animal Care and Use Committee (IACUC) guidelines 
(Protocol #: 27-09-06R) entitled “Pharmacological and toxicological effects of pesticides 
on ion channels and ABC transporters expressed in Xenopus laevis oocytes” submitted by 
J.M. Clark, principle investigator. 
 
2.3 CaV2.2 RNA Preparation 
Full length CaV2.2 cDNA α1 and β3 clones were provided as a gift from Dr. Diane 
Lipscombe (Brown University, Providence, R.I.). Linearized cDNA was checked by 
electrophoresis on a 0.8 % agarose gel against a High Mass DNA Ladder (10496-016; 
Invitrogen).  cDNA isolation and purification were performed following manufacturer’s 
instructions for the QIAquick
®
 Gel Extraction Kit (QIAGEN, Valencia, CA). In vitro 
transcription was performed using the mMessage mMachine
®
 High Yield Capped RNA 
Transcription Kit (# AM1344; Ambion Inc., Austin TX) (Lin et al., 1997; Symington and 
Clark, 2005; Symington et al., 2007a).  
Specifically, CaV2.2 α subunit cRNA was prepared for oocyte injection from the 
cDNA clone RNα1B-d (vector pBSTA rscg1B-b, 3.19 kb). The β3 auxiliary subunit cRNA 
was prepared from the cDNA clone (vector pcDNA3.1zeo+, 5 kb). CaV2.2 and β3 cDNAs 
were checked on a 0.8% agarose gel (0.4 g agarose, 50 ml 1X Tris-Acetate EDTA (TAE) 
buffer and 1 µl ethidium bromide (10 mg/ml)) run at 100 mV for 1 hr and measured 
against a High Mass DNA Ladder.    
cDNA isolation and purification was performed using the QIAquick
®
 Gel 
Extraction Kit.  Three volumes of Buffer QG and 1 volume of isopropanol were added to 
the reaction mixture and mixed by repetitive pipetting until homogenous.  The entire 
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sample was applied to the supplied spin column and centrifuged for 1 min at 15,690g. 
The flowthrough was removed from the catch tube.  PE buffer (0.75 ml) was added to the 
spin column and after a 1 min equilibration interval the column was recentrifuged as 
before. The spin column was transferred to a new centrifuge tube. The concentration of 
cDNA was determined by gel electrophoresis on a 0.8% agarose gel stained with 
ethidium bromide and measured against a High Mass DNA Ladder prior to isolation and 
purification so that an appropriate amount of elution buffer (EB) could be added to ensure 
that the cDNA concentration after isolation and purification was equal to 1 μg/μl (20-50 
μl). The appropriate amount of EB was added and the spin column was recentrifuged. 
The purity of the eluted cDNA was checked by electrophoresis on a 0.8% agarose gel 
stained with ethidium bromide at 100 mV for 1 hr and measured against a High Mass 
DNA Ladder. The remainder of the cDNA was stored at -20
o
C until used for in vitro 
transcription. cDNA concentration was determined using a ND-1000 UV-Vis 
Spectrophotometer (Thermo Fisher Scientific Wilmington, DE). The ND-1000 UV-Vis 
Spectrophotometer forms a column of sample (2 μl of purified DNA) between the sample 
pedestal and the arm of the spectrophotometer. The pedestal moves to automatically 
adjust the length of the sample column for an optimal path length (0.05 mm to 1.0 mm) 
for measurement of the optical density (absorbance) of the sample at 260 nm. 
Concentration of the sample is calculated using the Beer-Lambert Law (Equation 1):  
 
Equation 1 
 A = εcl 
Where: 
A = the absorbance of the sample at 260 nm  
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ε = the absorption coefficient of DNA (50) 
c = the concentration of the sample 
l = the path length 
 
In vitro transcription was performed using the mMessage mMachine
®
 High Yield 
Capped RNA Transcription Kit. To the CaV2.2 α1 and  β3 reaction mixtures, 1 μl of 30 
mM GTP cap, 2 μl of 10X Reaction Buffer, 1 μg of either α1 or β3 CaV2.2 DNA, 10 μl of 
2X NTP cap, 2 μl of 2X Enzyme mix and RNase-free ddH2O (diethyl pyrocarbonate 
(DEPC)-treated) up to 20 μl were added and mixed. The reaction was incubated at 37oC 
for 2 hr, 2 U/μl Turbo DNase was added, and the mixture incubated for an additional 15 
min. The reaction was stopped by adding 30 μl nuclease free ddH2O and 30 μl of the 
LiCl2 solution provided to precipitate the cRNA. Reaction mixtures were chilled for 
approximately 30 min at -20
o
C before pelleting the cRNA by centrifuging at 4
o 
C for 15 
min at 16,170g. After decanting the supernatant, the cRNA pellet was washed with 70% 
ethanol and re-centrifuged. Ethanol was removed via pipette and the cRNA resuspended 
in 12 µl RNase free ddH2O. cRNA was electrophoressed on a 1% agarose gel (0.5 g 
RNase free agarose, 36 ml of 0.01% DEPC-treated ddH2O ) and measured against a RNA 
marker (0.2- 10 kb, R-7020; Sigma Aldrich St. Louis, MO). The gel was run at 50 mV for 
3-5 hr at 4
o
C.  The running buffer was 450 ml of 0.01% DEPC-treated ddH2O and 50 ml 
of 10X MOPS (Swanson and Folander, 1992). cRNA concentration was determined using 
a ND-1000 UV-Vis Spectrophotometer (RNA absorption coefficient = 40) as described 
above and cRNA was stored at -80
o
C. 
 
2.4 Xenopus Surgery and Oocyte Preparation 
Oocytes were obtained surgically from a female Xenopus laevis frog anesthetized 
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in a 3-aminobenzoic acid ethyl ether (tricane) solution (2 g/L). Excised oocyte lobes were 
washed with OR2 solution (82.5 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM N-(2-
hydroxyethyl)piperazine-N′-2-ethanesulfonic acid (HEPES), pH 7.5). Most of the oocyte 
follicle membranes were digested with equal parts collagenase solution (Sigma Type 1A 
collagenase; 0.5 U/ml (2 mg/ml)) and OR2 solution. The remaining follicle membranes 
were removed manually using fine forceps under a stereomicroscope. Healthy stage V-VI 
oocytes were maintained at 19
o
C in oocyte supplemental media (ND96 media (96 mM 
NaCl, 2 mM KCl, 1.8 mM CaCl2·2H2O, 1 mM MgCl2·6H2O, 5 mM HEPES, pH 7.5) 
supplemented 1% sodium pyruvate, 2% antibiotics (penicillin, streptomycin) and 5% 
horse serum) (Goldin, 1992).  
Surgery was done under semi-sterile conditions following IACUC procedures 
outlined in Protocol No. 27-09-06R. A female frog (7.5-9 cm) was placed into a tricane 
solution (2 g/L) for 10-15 min. Anesthesia was checked by placing the frog upside down 
to see if she could right herself and by lack of foot-pinch reflex. If anesthesia was not 
complete, the frog was left in the tricane solution for up to 30 min. The anesthetized frog 
was placed on its back on a clean, wet surface. A 1.0 cm incision was made from the 
lower medial to lateral abdomen toward the head using a sterile surgical blade cutting 
through both the skin and underlying membrane. Ovary lobes were pulled through the 
incision with a pair of forceps until a sufficient number of oocytes (about 200-300) were 
exposed and removed by cutting the connective follicle membrane with a pair of 
dissecting scissors. The remaining ovary lobes were placed back into the frog’s abdomen 
and the inner and outer membrane incisions were closed separately using a surgical suture 
(4-0 chromic gut, Angiotech, Reading, PA) (Goldin, 1992). Excised oocyte lobes were 
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washed three times with 20-30 ml of OR2 solution, placed in a 15 ml conical vial 
containing 5 ml collagenase solution (Type 1A collagenase; 0.5 U/ml (2 mg/ml)) and 5 
ml OR2 solution,  and incubated on an orbital shaker at 35 rpm at room temperature for 
15-18 min or until the solution became cloudy. Collagenase/OR2 solution was discarded, 
replaced every 7-9 min with fresh solution, and treatment was continued until 
approximately half the oocytes were fully defollicated. The remaining follicle membranes 
were removed manually using fine forceps under a stereomicroscope. Healthy stage V-VI 
oocytes were selected based on uniform pigmentation, size and shape. They were 
maintained at 19
o
C in oocyte supplemental media.  
 
2.5 cRNA Injection 
Stage V and VI oocytes were co-injected with 46 nl of a cRNA solution 
containing the α1 (stock solution 1 μg/μl) and the β3 (stock solution 0.33 μg/μl) subunits 
of CaV2.2 using a nanoliter 2000 injector (World Precision Instruments, Sarasota FL) in 
25 nl increments. Injected oocytes were stored in  oocyte supplemental media at 19
o
C 
until used in expression experiments (Shih et al., 1998).  
 
2.6 Electrophysiology 
The function of wild type CaV2.2 α1B subunit co-expressed with the β3 subunit in 
the Xenopus oocytes was assayed using the two-electrode voltage clamp (TEVC) 
technique by measuring inward Ba
2+
 currents. The function of wild type CaV2.2 α1B 
subunit co-expressed with the β3 subunit in the Xenopus oocytes was assayed using the 
two-electrode voltage clamp (TEVC) technique by measuring inward Ba
2+
 currents. 
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The function of wild type CaV2.2 α1B subunit co-expressed with the β3 subunit in 
the Xenopus oocytes was assayed using the TEVC technique. Recordings were made in 
siliconized culture well oocyte recording chambers (250 l bath volume; C7485-20EA, 
Sigma-Aldrich, St. Louis, MO) containing Ba
2+
 recording solution (5 mM BaCl2, 85 mM 
tetraethylammonium, 5 mM KCl, 5 mM HEPES, adjusted to pH=7.4 with 
methanesulfonic acid) using a GeneClamp 500B amplifier (Axon Instruments, Union 
City, CA). Voltage and current microelectrodes with resistances between 0.5-3.0 M 
were made from borosilicate glass using a Narishige PP-83 electrode puller and filled 
with 3 M KCl. The electrodes were coated with silver conductive paint (CW2200STP, 
Chemtronics, Kennesaw, GA), over coated with insulating resin (CW3300C, 
Chemtronics), and shielded with grounded aluminum foil to minimize noise. Data were 
digitized at 20 kHz using the Digidata 1322A digitizer, stored by the pClamp (ver. 9.2, 
Axon Instruments, Union City, CA) software, and capacitive transient current subtracted 
online using the P4 protocol.  
Waveform protocols for the Transient, Activation, Inactivation and Deactivation 
Test Protocols are shown in Figure 2. To test for CaV2.2 channel expression, the Transient 
Test Protocol was applied to each oocyte by depolarizing the plasma membrane from a 
resting potential of -80 mV to 10 mV for 150 ms and returning to resting potential (Fig. 
2A).  Recordings were made every minute for 10 minutes to judge the time course of the 
effects of each of the pyrethroids and PMA on Ba
2+
 peak current via expressed CaV2.2. 
From these recordings, the treatments effects on transient peak current (the most  
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Figure 2. Waveform protocols for Transient, Activation, Inactivation and Deactivation 
tests. (A) Transient peak current, activation tau and deactivation tau can be 
measured directly from the Transient Test Protocol. (B) V50inact and 
Inactivation tau, the rate of closure during depolarization, are best measured 
from the Inactivation Test Protocol. V50inact is measured as a function of 
increasing levels of long-term (2 s) depolarizations. (C) The Deactivation Test 
Protocol measures the rate of channel closure (deactivation tau) as a function of 
decreasing levels of repolarization. (D) To best measure activation tau (ms), the 
Activation Test Protocol measures the rate of activation as a function of 
increasing levels of depolarization. Orange lines indicate a sample sweep from 
the Activation, Inactivation and Deactivation Test Protocols.  
 
  36 
B. Inactivation Test
-120 mV
0 mV
2 s 50 ms
-80 mV
0 mV
10 ms 100 msC.
Deactivation Test
-80 mV
40 mV
10 msD.
Activation Test
INACTIVATION DEACTIVATION
Deactivation tau (ms)Activation tau (ms)
-80 mV
10 mV
Depolarization Repolarization
150 ms
Baseline
ACTIVATION
A. Transient Test
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negative amplitude of current evoked from the depolarization step; μA), steady-state 
activation tau (the rate of channel opening during the depolarization step; ms), steady-
state inactivation tau (the rate of channel inactivation during the depolarization step; ms) 
and steady state deactivation tau (the rate of channel closing after the removal of the 
depolarization step; ms) at 4 min and 10 min post treatment were obtained and used for 
statistical analysis.   
In the Activation Test Protocol, the membrane potential was step-depolarized in 
10 mV increments from a resting potential of -80 mV to a final level of 40 mV. The 
duration of each depolarization step is 10 ms before the membrane potential is 
repolarized back to -80 mV (Fig. 2B). The Activation Test Protocol was used to 
determine the effect our treatments have on CaV2.2 voltage dependent peak current, 
voltage-dependent activation taus, and voltage-dependent activation midpoint potentials 
(V50act).   
The Inactivation Test Protocol has two depolarization phases. The first lasts for 2 
s and undergoes step-depolarization by an additional 10 mV per sweep starting at -120 
mV and ends with a final step depolarization to 0 mV. Each sweep of the first phase of 
the Inactivation Test Protocol is immediately followed by the second phase of the 
protocol, which is the depolarization of the membrane from the current level of the first 
phase to 0 mV for 50 ms (Figure 2C). Recordings were made at 4 min and 10 min post 
application of treatment. Using the Inactivation Test Protocol, we were able to determine 
what effects our treatments had on CaV2.2 voltage-dependent inactivation midpoint 
potential (V50inact) based on the measurement of late current.   
The Deactivation Test Protocol also has two phases: a depolarization phase and a 
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repolarization phase. During the depolarization phase of the protocol, the membrane is 
depolarized from a resting potential of -80 mV to 0 mV for 10 ms. The repolarization 
phase occurs immediately following the depolarization phase. During the repolarization 
phase, the membrane is repolarized in decreasing steps by 10 mV starting with the 
repolarization step to -80 mV during the first sweep and ending at 0 mV during the last 
sweep. Each repolarization level is held for 100 ms and recordings were made at 4 min 
and 10 min post treatment (Figure 2D). The Deactivation Test Protocol was designed to 
determine what effects our treatments have on voltage-dependent deactivation taus.   
 
2.7 Measuring PMA and Pyrethroid Effects on CaV2.2 Inward Transient Peak 
Current 
Initially, a Transient Test Protocol was applied to the oocyte to determine VGCC 
expression (Fig. 2). Non-treated peak current (amperage, A), activation (ms), and 
deactivation tau (ms) values were obtained from oocytes when CaV2.2 expression levels 
produced peak currents ≥ 0.5 μA. Peak current (ICa
2+
)
 
was determined as the most 
negative amplitude value from the raw current trace produced by the Transient Test. 
Activation and deactivation taus were measured using the exponential standard (zero-
shift) curve (Clampfit ver. 9.2, Axon Instruments) by Equation 2: 
 
Equation 2 
                 n 
  f(t) = ΣAie
-τi  
+ C 
           
i=1 
 
Where:  
A = Amplitude 
τ = time constant 
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C = constant y-offset 
i = component to be measured 
 
Activation measures the part of the current curve from the start of depolarization 
to peak current amplitude and activation tau (η) represents the amount of time required to 
open 50% of the channels during membrane depolarization. Deactivation tau measures 
the part of the current curve displaying channel activity after membrane depolarization 
was removed (repolarization step) and represents the amount of time required to close 50 
% of the channels (Clampfit 9.2). Midpoint potentials for activation and steady-state 
inactivation were determined by least squares fits of current-voltage relationship from 
individual experiments to the Boltzmann equation (Equation 3) using GraphPad Prism.   
 
Equation 3 
Y = Bottom +  (Top – Bottom) 
  1+exp (V50 – X) 
   slope 
 
Treated values (DMSO, PMA and pyrethroid) were obtained from CaV2.2 test 
protocols that were run after application of treatments. Only one type of treatment was 
applied to each oocyte.  Pulse protocols were applied at 4 min and 10 min post treatment 
and the raw traces that resulted from each pulse were saved to obtain data values specific 
to each time point (Clampex). Raw data values were obtained using Clampfit 9.2. Data 
obtained from each time point (min post treatment) were normalized to the non-treated 
control using Equation 2.  
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Equation 4    
Normalized Value =          Treated value      • 100% 
         Non-treated value 
 
 
2.8 Statistical Analysis of Data 
Analysis of the electrophysiology data was conducted using a combination of 
Clampfit 9.2 and Graph Pad Prism (GraphPad Software, Inc, San Diego CA) and 
Microsoft Excel (2003 Microsoft Corporation, Seattle WA). Averages and standard error 
means were calculated for normalized values from each individual treatment. Averages 
were statistically compared to the averaged normalized DMSO control values from each 
corresponding time point and step depolarization using a one-way ANOVA with a 
Bonferonni Post test comparing selected pairs of treatments (GraphPad Prism, P= 0.05 
unless otherwise noted).    
For example, peak current (PC) values are recorded as the highest current 
amplitude obtained during the Transient Test Protocol. From each oocyte, 11 recordings 
are made:  no treatment (NT), and one recording per minute for 10 min post treatment. 
The 4 min post treatment (4 min) and 10 min post treatment (10 min) recordings are used 
for statistical analysis. Each oocyte is treated only once by direct application of the 
treatment compound to the recording solution after the NT recording is made. Four min 
and 10 min PC recordings are normalized to the NT from the same oocyte from which 
they were recorded (Equation 4). Normalized PC recordings are averaged together by 
time point and treatment and a standard error of the mean (SEM) was calculated for each 
average. Unless otherwise noted, the average and SEM data from each treatment were 
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statistically compared to normalized DMSO PC using one-way ANOVA with Bonferonni 
Post test.    
In the Activation, Inactivation, and Deactivation Test Protocols, recordings are 
made at 4 min and 10 min post treatment using 5 mM Ba
2+
 as the charge carrier. From the 
Activation Test Protocol, voltage dependent peak current (mV ± SEM), activation 
midpoint potential (mV
-1
 ± SEM), and voltage-dependent activation (mV
-1
 ± SEM) data 
were collected. Activation midpoint potential and voltage-dependent activation are 
reported as V50 act and ηactivation (ms), respectively. The slope and intercept for determining 
voltage-dependent activation are reported as ηactivation slope (mV
-1
 ± SEM) and ηactivation y-
intercept. From the Inactivation Test Protocol, the inactivation midpoint potential data 
were collected and reported as V50inact (mV± SEM). From the Deactivation Test Protocol, 
voltage-dependent deactivation data were calculated and reported as the ηdeactivation (ms). 
The slope and intercept for determining voltage-dependent deactivation are reported as 
ηdeactivation slope (mV
-1
 ± SEM) and ηdeactivation y-intercept. Data from the Activation, 
Inactivation and Deactivation Test Protocols were statistically compared using the 
Student’s T-test.  Unless otherwise reported, P < 0.05).   
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Figure 3:  Overview of the method used to express and analyze CaV2.2.  α- and β- subunit cDNAs are cloned, amplified and purified 
and used to produce cRNAs by in vitro transcription.   α- and β-subunit cRNAs are injected in to Xenopus laevis  oocytes for 
heterologous expression which is verified using two-electrode voltage clamp (TEVC) technique. Using TEVC, CaV2.2 is 
subjected to Transient, Activation, Inactivation and Deactivation Test Protocols from which measurements are taken to 
determine the transient peak current, activation  taus, inactivation taus, deactivation taus, current-voltage relationships, 
voltage-dependent peak current, voltage-dependent activation  rate, activation midpoint potential, inactivation midpoint 
potential and voltage-dependent deactivation rate under control and treated conditions, Values are statistically compared 
using either One-way ANOVA with Bonferonni Post Test or Student’s T-test (P < 0.05).  
 
4
2
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CaV2.2 and β3 cDNAs obtained for amplification and purification.
Xenopus laevis oocytes injected with cRNAs (Shih et al. 1998; Soderlund et al. 2002).
Expression of CaV2.2 verified using the TEVC technique
Measurements taken from CaV2.2 current traces expressed in Xenopus oocytes by TEVC.
Values were normalized to either their respective No Treatment values or DMSO. Steady-state 
data was analyzed using one-way ANOVA with Bonferonni post-test was used to determine the statistical
differences between treatments (P<0.05) and voltage-dependent data was statistically analyzed using T-
tests (P<0.05).
CaV2.2 and β3 cRNAs produced by in vitro transcription (Symington 2005)
10 ms
-80 mV
40 mV
Activation Test
-80 mV
10 mV
150 ms
Transient Test
Inactivation Test
-120 mV
0 mV
50 ms2 s
-80 mV
0 mV
10 ms 100 ms
Deactivation Test
4
3
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Table 2: Types of data endpoints obtained from the Transient, Activation, Inactivation, and Deactivation Test protocols. 
 
 
Transient Activation Inactivation Deactivation
Transient Peak Current 
(μAT/μANT x 100)
Voltage-dependent peak 
current (mV)
Inactivation MPP                      
(mV ± SEM)
Voltage-dependent 
deactivation (ηdeactivation)
Activation tau 
(msecT/msecNT x 100)
Activation MPP        
(mV ± SEM)
ηdeactivation slope                 
(mV
-1
± SEM)
Inactivation tau 
(msecT/msecNT x 100)
Voltage-dependent 
activation (ηactivation)
ηdeactivation y-intercept
Deactivation tau 
(msecT/msecNT x 100)
ηactivation slope                    
(mV
-1
± SEM)
ηactivation y-intercept
Protocol
Endpoints
4
3
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CHAPTER 3 
PMA INCREASES TRANSIENT PEAK CURRENT AND CHANGES THE GATING 
KINETICS OF CAV2.2 
 
3.1 Results 
3.1.1 Steady-state Peak Current 
Using the Transient
 
Test Protocol, maximal effects on transient peak current under 
steady-state depolarization were observed for wild type CaV2.2 in the presence of DMSO, 
PMA and 4α-PMA over the course of a 10 min incubation period (Fig. 4A). PMA 
treatment of expressed CaV2.2 phosphorylates the channel due to the activation of PKC. 
Under basal conditions in the absence of PMA CaV2.2 is unphosphorylated (Stea et al., 
1995). The presence of PMA at 4 min post treatment caused the largest and most 
significant difference in transient peak current (49%) compared to the DMSO control. At 
4 min post treatment, transient peak current in the presence of 4α-PMA was significantly 
less (-31%) than transient peak current in the presence of PMA. The presence of PMA 
caused a significant 40% increase compared to the effect of DMSO on transient peak 
current at 10 min post treatment. In the presence of 4α-PMA at 10 min post treatment, 
transient peak current was not significantly different from transient peak current in the 
presence of DMSO or PMA (Fig. 4B; Table 3).  
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Figure 4.  The effects of 0.1 % DMSO, the phorbol ester PMA (8 x 10
-7
 M) and its 
enantiomer 4α-PMA (8 x 10-7 M) on relative transient peak current of wild 
type CaV2.2 over 10 min.  A diamond (♦) indicates significant difference from 
DMSO treatment.  A circle (●) indicates significant difference from PMA 
treatment. The number of eggs (n) used for these treatments are: DMSO (n = 
39); PMA (n = 51); 4α-PMA (n = 12). Significance was calculated using One-
way ANOVA with Bonferroni’s Multiple Comparison post test (P<0.05). 
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3.1.2 Steady-state Gating Kinetics 
Steady-state activation, inactivation and deactivation taus were obtained using the 
Transient Test Protocol (Fig. 2). At 4 min post treatment, activation taus in the presence 
of PMA were not significantly different from the DMSO control, but at 10 min post 
treatment, there was a 21% significant increase in the activation tau in the presence of 
PMA (Fig. 5B). In the presence of 4α-PMA at both 4 and 10 min post treatments, 
activation taus were not significantly different from DMSO control (Fig. 5A and 5B and 
Table 3).  
 The rate of the inactivation tau did not change significantly in the presence of either 
PMA or 4α-PMA at both 4 min and 10 min post treatments (Fig. 5C and 5D and Table 3). 
Although not statistically different, the inactivation tau at 4 min post treatment decreased 
(-42%) compared to the DMSO control, indicating that there may be a trend that CaV2.2 
inactivates faster in the presence of PMA (Fig. 5C).  
Steady-state deactivation taus in the presence of PMA at 4 and 10 min post 
treatment were increased by 41 and 54%, respectively, compared to the DMSO controls 
(Fig. 5E and 5F) indicating that the rate of channel closure after removal of the 
depolarization step was slowed. In the presence of 4α-PMA, deactivation taus were not 
statistically different compared to those in the presence of DMSO at 10 min post 
treatment. However, at 4 min post treatment, 4α-PMA significantly reduced the 
deactivation tau 4 min post treatment by 28% compared to the effect of PMA.  
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Figure 5.  The effects of 0.1 % DMSO, the phorbol ester PMA (8 x 10-7 M) and its 
inactive enantiomer 4α-PMA (8 x 10-7 M) on steady-state kinetics of wild type 
CaV2.2 at 4 and 10 min post treatment.  Activation (A and B), inactivation (C 
and D) and deactivation (E and F) taus were normalized to their respective  no 
treatment controls.  The number of eggs (n) used to calculate activation and 
deactivation taus at 4 min post treatment were DMSO (n = 38); PMA (n=51); 
4α-PMA (n=11) and at 10 min were DMSO (n=38); PMA (n=50); 4α-PMA 
(n=12). The number of eggs (n) used to calculate inactivation taus at 4 min 
post treatment were DMSO (n=16); PMA (n=16); 4α-PMA (n=3) and at 10 
min post treatment, were DMSO (n=12); PMA (n= 17); 4α-PMA (n=4). 
Significance was calculated using One-way ANOVAs with Bonferroni’s 
Multiple Comparison post test (P<0.05). 
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3.1.3 Voltage-dependent Peak Current 
The effects of PMA on average voltage-dependent kinetics of CaV2.2 were 
determined using current-voltage relationships (I/V curves) obtained using the Activation 
Test Protocol (Fig. 2). Voltage-dependent peak current significantly increased by 44% 
and 64%, in the presence of PMA compared to the normalized No Treatment and DMSO 
controls respectively at 4 min post treatment (Fig. 6A and Table 4). At 10 min post 
treatment, voltage-dependent peak current significantly increased in the presence of PMA 
by 39% at 10 min post treatment (Fig 6B). The increases in peak current in the presence 
of PMA at both 4 and 10 min post treatment are consistent with previous reports (Stea et. 
al, 1995). Treatment with 4α-PMA also resulted in significant 24% increase in voltage-
dependent peak currents at 4 min post treatment (Fig. 6A and Table 4). The difference in 
the average voltage-dependent peak current in the presence of PMA and in the presence 
of 4α-PMA at 4 min post treatment was not significantly different (Table 4).  The effect 
of 4α-PMA on peak current at 10 min post treatment was greater but was not significantly 
different from the effect of 4α-PMA 4 min post treatment. At 10 min post treatment, the 
effect of 4α-PMA treatment on average peak current was not significantly different from 
that of the PMA treatment.   
 
3.1.4 Voltage-dependent Gating Kinetics 
The activation midpoint potential (V50act) at 4 min post treatment was not altered 
by any of the treatments compared to the no treatment control (Table 4). Significant 
depolarizing shifts in the activation midpoint potential, however, were observed for both 
the DMSO (88%) and 4α-PMA (238%) treatments compared to the no treatment control  
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Table 3. The effects of DMSO, PMA and 4α-PMA on CaV2.2 steady-state transient peak current, activation, inactivation and 
deactivation taus at 4 and 10 min post treatment.  
 
5
1
 
No Treatment DMSO PMA 4α-PMA
Transient Peak Current 
(μAT/μANT x 100)
100 ± 0.0 106.6 ± 3.2  158.9 ± 7.3         
♦(49)
  110.3 ± 4.0    
●(-31)
Activation tau (η)         
(msecT/msecNT x 100)
100 ± 0.0 108.4 ± 1.8 104.1 ± 2.2 107.1 ± 2.6
Inactivation tau (η) 
(msecT/msecNT x 100)
100 ± 0.0 124.1 ± 12.5 72.24 ± 8.4     
♦(-42)         
82.9 ± 10.5
Deactivation tau (η) 
(msecT/msecNT x 100)
100 ± 0.0 104.0 ± 6.6 146.6 ± 9.1       
♦(41)
105.0 ± 8.6       
● (-28)
Transient Peak Current 
(μAT/μANT x 100)
100 ± 0.0 102.1 ± 4.5 141.9 ± 8.9       
♦(40)
114.5 ± 7.8       
●(-19)
 
Activation tau (η) 
(msecT/msecNT x 100)
100 ± 0.0 108.4 ± 1.8 131.6 ± 4.8    
♦(21)
 
115.2 ± 4.5
Inactivation tau (η) 
(msecT/msecNT x 100)
100 ± 0.0 166.3 ± 32.5 158.9 ± 38.1 99.54 ± 36.5
Deactivation tau (η) 
(msecT/msecNT x 100)
100 ± 0.0 104.0 ± 6.6 160.3 ±  13.3    
♦(54)
 
105.4 ± 7.1
Treatment (10
-7
 M)
4 min 
10 min
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A closed diamond (♦) indicates significant difference from DMSO.  A closed circle (●) indicates significant difference from 
PMA. Both were determined by one-way ANOVA (P <0.05). Values in parentheses are percent increases or decreases. 
5
2
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value (Fig. 5D) at 10 min post treatments. The effects of PMA and 4α-PMA treatments on 
V50acts were not significantly different from the DMSO treatment or from each other at 10 
min post treatment.   
Treatments with PMA and 4α-PMA did modify the voltage-dependent 
inactivation kinetics compared to the controls (Fig. 6, Table 4). A hyperpolarizing shift in 
V50inact is an indication that the channels are inactivating at lower potentials allowing for 
decreased Ca
2+
 influx.  At 4 min post treatment, DMSO caused a significant 25% 
hyperpolarizing shift in V50inact compared to the no treatment control (Fig. 6E). There was 
no significant effect, however, at 10 min post treatment. In the presence of PMA, at 4 min 
post treatment significant 40% and 24% hyperpolarizing shifts in the V50inact compared to 
the no treatment and DMSO control, respectively, were observed (Fig. 6E, Table 4). The 
presence of PMA at 10 min post treatment (Fig. 6F) caused an even greater 
hyperpolarizing shift of V50inact compared to no treatment (80%) and DMSO (69%) 
values.  
4α-PMA did not significantly alter the voltage-dependent inactivation kinetics 
compared to the no treatment control, however, a 34% depolarizing shift in V50inact was 
observed in the presence of 4α-PMA at 4 min post treatment compared to DMSO 
treatment. 4α-PMA did result in significant depolarizing shifts in the V50inact compared to 
the PMA treatment at 4 (49%) and 10 (50%) min post treatment (Table 4).   
The effects of PMA on the activation and deactivation kinetics of CaV2.2 are 
shown in Figure 7 and Table 5. At 4 min post treatment, there were no significant 
differences between treatments on the voltage-dependent rates of activation (ηactivation) 
(Table 5). In the presence of DMSO at 10 min post treatment, ηactivation was significantly 
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Figure 6.  Effects of 0.02% DMSO, PMA (1 x 10
-7
 M) and its inactive analog 4α-PMA (1 
x 10
-7
 M) on voltage-dependent peak current, activation midpoint potential and 
inactivation midpoint potential at 4 and 10 min post treatment. (A and B) 
Voltage-dependent peak current was normalized to the DMSO control (value of 
DMSO treatment normalized to 1). (C and D) Activation midpoint potentials 
(V50act) and (E and F) inactivation midpoint potential (V50inact) were determined 
by the least-squares fits of the current-voltage relationship from individual 
experiments of the Activation and Inactivation Test Protocols using the 
sigmoidal dose-response (variable slope) equation. The number of eggs (n) 
used for the calculations of voltage-dependent peak currents, and V50act were no 
treatment (n= 40); DMSO (n = 19); PMA (n = 17); 4α-PMA (n = 5). (E and F). 
The number of eggs (n) used for the calculations of V50inact were no treatment 
(n= 30) DMSO (n = 13); PMA (n = 13); 4α-PMA (n = 5). Statistical analysis 
was conducted using Student’s T-test (P < 0.05). 
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greater than no treatment control by 14% at 30 mV.  In the presence of PMA at 10 min 
post treatment, there were significant increases in ηactivation values that ranged from 16-
29% following membrane depolarizations from -20 mV to 30 mV of 16-29% compared 
to DMSO control values.  Conversely, 4α-PMA caused significant decreases in ηactivation 
values at 10 min post treatment that ranged from 21-27% following membrane 
depolarization from -30 mV to -10 mV compared to DMSO control values. The ηactivation 
values in the presence of 4α-PMA at 10 min post treatment were significantly less than 
those following PMA treatment and ranged from 18-37% following membrane 
depolarizations from -10 mV to 20 mV.  
At 4 min post treatment, ηactivation slope in the presence of DMSO was significantly 
different from the no treatment control (Table 6). In the presence of PMA, ηactivation slope 
had no significant effect compared to the DMSO control at 4 min post treatment (Figure 
7). The ηactivation slope in the presence of 4α-PMA was significantly different compared to 
either DMSO or PMA treatments at 4 min post treatment (Table 6).  
At 4 and 10 min post treatment, ηactivation y-intercept in the presence of DMSO was 
significantly different from the no treatment control treatment (Table 6). The effect of 
PMA on ηactivation y-intercept was not significant at 4 min post treatment but was 
significantly different at 10 min post treatment from DMSO. The ηactivation y-intercept in 
the presence of 4α-PMA was significantly different from both DMSO and PMA at 4 and 
10 min post treatments.  
The effect of PMA on the voltage-dependent ηdeactivation at 4 min post treatment was 
significantly greater than the voltage-dependent ηdeactivation in the presence of DMSO at -40 
mV and -30 mV by 29% and 41% respectively (Table 7). The effect of 4α-PMA on 
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Table 4. The effects of DMSO, PMA and 4α-PMA on CaV2.2 voltage-dependent peak current, activation and 
inactivation midpoint potentials. 
  
An open diamond (◊) indicates significant difference from no treatment. A closed diamond (♦) indicates 
significant difference from DMSO.  A closed circle (●) indicates significant difference from PMA. Statistical 
differences were determined by using Student’s T-test (P <0.05). Values in parentheses are percent increases or 
decreases. 
 
No Treatment DMSO PMA 4α-PMA
Voltage-dependent 
peak current
-0.98 ± 0.01 -0.86 ± 0.07         
◊(-12)
-1.41 ± 0.15 
◊(44) ♦(64)
-1.22 ± 0.16 
◊(24) ♦(42)
Activation MPP          
(mV ± SEM)
-1.85 ± 0.43 -1.71 ± 0.65 -0.93  ± 0.75 -3.09 ± 0.40
Inactivation MPP                
(mV ± SEM)
-27.73 ± 2.21 -34.40 ± 2.34 
◊(25)
 
-42.62 ± 9.31              
◊(-40) ♦(-24)
 
-21.58 ± 4.21      
♦(34) ●(49)
Voltage-dependent 
peak current
-0.98 ± 0.01 -0.64 ± 0.07 
◊(35)
-1.03 ± 0.16 
♦(39)
-0.97 ± 0.06
Activation MPP        
(mV ± SEM)
-1.42 ± 0.52 -0.22 ± 0.74    
◊(88)
 
-1.40 ± 0.47 
 
2.56 ± 1.82      
◊(238)
Inactivation MPP      
(mV ± SEM)
-25.78 ± 2.28 -27.49 ± 2.62  -46.36 ± 6.01   
◊(-80) ♦(-69)
 
-23.19 ± 4.46   
●(50)
Treatment (10
-7
 M)
4 min 
10 min 
5
7
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ηdeactivation at 4 min post treatment was significantly less than DMSO treatment by 40% at -
30 mV. At 10 min post treatment the presence of DMSO caused significant increases in 
ηdeactivation values that ranged from 20-21% following membrane depolarizations from -50 
mV to -30 mV.  
The ηdeactivation values in the presence of PMA at 10 min post treatment were 
significantly greater than those following DMSO treatment and ranged from 44%-86% 
following membrane depolarizations from -50 mV to -30 mV. ηdeactivation in the presence of 
4α-PMA was not significantly different from either DMSO or PMA treatments at 10 min 
post treatment. 
The ηdeactivation slope following PMA treatment was significantly greater than the 
DMSO control value 4 min (Fig. 7C) and 10 min (Fig. 7D) post treatment (Table 6). In 
the presence of 4α-PMA at both the 4 and 10 min post treatment, the ηdeactivation slope was 
reduced by -65% and -70%, respectively, compared to the effect of PMA treatment (Table 
6). The effect of PMA on the ηdeactivation y-intercept was significantly greater than the 
effect of the DMSO control at both 4 min and 10 min post treatments. The ηdeactivation y-
intercept in the presence of 4α-PMA was significantly less than the effect of PMA at 
either 4 or 10 min post treatment by -70% or -49%, respectively (Table 6). 
 
3.2 Discussion 
3.2.1 Steady-state peak current 
Our results confirm earlier reports that  under steady-state conditions, the phorbol 
ester PMA is a potent activator of the endogenously expressed PKC in Xenopus oocytes 
resulting in altered Cav2.2 currents  (Bourinet et al., 1992). PMA is capable of  
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Figure 7.  Semi-logarithmic plots of the activation tau (A and C) and deactivation tau (C 
and D) values resulting from the effects of 0.02% DMSO, PMA (1 x 10
-7
 M) 
and its inactive analog 4α-PMA (1 x 10-7 M) at 4 min (A and B) and 10 min 
(C and D) post treatment using the Activation and Deactivation Test Protocols, 
respectively. Activation and deactivation tau values are obtained from linear 
regression fits to the data. The voltage dependence of activation and 
deactivation are represented by slope. The rates of activation and deactivation 
are represented by the y-intercept. The number of eggs (n) used for A and C 
are:  no treatment (n = 41); DMSO (n = 18); PMA (n = 17); 4α-PMA (n = 5).  
The number of eggs (n) for B and D are: no treatment (n = 30); DMSO (n = 
21); PMA (n = 11); 4α-PMA (n = 5). Statistical analysis was conducted using 
Student’s T-test (P < 0.05).  
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phosphorylating several different sites on the intracellular loops of CaV2.2 and result in a 
variety of altered expression patterns and kinetic properties of this channel (Fang et al., 
2006). 
In support of previous findings (Stea et al., 1995), phosphorylated CaV2.2 allowed 
an increase of transient Ba
2+ 
peak current under steady-state depolarizing conditions.  
The same time-dependent effects of phosphorylated CaV2.2 transient peak current 
observed by Stea et. al. (1995) were seen in our assay with a similar run down of Ba
2+
 
currents by the 10 min time point and a maximal effect on peak current occurring at 4 
min post treatment.  
4α-PMA, the inactive structural analog of PMA, had no effect on Ba2+ influx. A 
similar effect of 4α-PMA on transient peak current was also reported by Stea et al. 
(1995), but using the R-type Ca
2+
 channels α1E. Although the Xenopus oocyte system is a 
non neuronal heterologous expression system, our findings are consistent with other 
studies where neuronal tissue preparations were used to show PMA-activated PKC 
increased transient peak current using superior cervical ganglion, and dorsal root 
ganglion nerve preparations that also show an increase in peak current in the presence of 
PMA-activated PKC(Swartz, 1993). When neuronal cell preparations were treated with 
PMA under depolarizing conditions, an increase in whole cell current and 
neurotransmitter release was observed (Swartz, 1993; Zhu and Ikeda, 1994; Barrett and 
Rittenhouse, 2000; García-Ferreiro et al., 2001). Thus, increases in Ba
2+
 peak current 
from heterologously expressed phosphorylated CaV2.2 in Xenopus oocytes under steady 
state depolarizing conditions is consistent with previous reports finding that PMA 
activates PKC endogenously expressed within the oocyte allowing phosphorylation of 
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Table 5. The effects of DMSO, PMA and 4α-PMA on CaV2.2 voltage-dependent activation (ηactivation). 
-30 -20 -10 0 10 20 30
Treatment    
(10
-7
M)
No Treatment 5.05 ± 0.41 3.93 ± 0.24 3.10 ± 0.15 2.46 ± 0.09 1.97 ± 0.07 1.58 ± 0.06 1.28 ± 0.05
DMSO 5.09 ± 0.28 4.08 ± 0.20 3.27 ± 0.14 2.64 ± 0.10 2.13 ± 0.07 1.73 ± 0.06 1.41 ± 0.05
PMA 5.78 ± 0.69 4.57 ± 0.46 3.63 ± 0.30 2.90 ± 0.20 2.33 ± 0.13 1.89 ± 0.10  1.53 ± 0.08
4α-PMA 4.25 ± 0.77 3.43 ± 0.52 2.78 ± 0.33 2.28 ± 0.21 1.88 ± 0.14 1.56 ± 0.13 1.31 ± 0.15
DMSO 4.78 ± 0.24 3.91 ± 0.17 3.20 ± 0.13 2.62 ± 0.10 2.15 ± 0.08 1.77 ± 0.07 1.46 ± 0.06
PMA 6.48 ± 0.87 5.07 ± 0.55 
♦(29)
4.00 ±0.35 
♦(25) 
3.18 ± 0.21 
♦(21)
2.55 ± 0.13 
♦(19)
2.13 ± 0.11 
♦(20)
1.70 ± 0.08 
♦(16)
4α-PMA 3.51 ± 0.79  
♦(-27)
2.96 ± 0.58 
♦(-24)
2.52 ± 0.40                
♦(-21) ●(-37)
2.16 ± 0.27 
●(-18)
1.87 ± 0.17 
●(-25)
1.64 ± 0.12 
●(-23)
1.45 ± 0.14
4 min 
Test Potential (mV)
tauactivation (ms)
10 min
 
 
An open diamond (◊) indicates significant difference from no treatment. A closed diamond (♦) indicates significant difference from 
DMSO. A closed circle (●) indicates significant difference from PMA. Statistical differences were determined by Student’s T-test (P 
6
2
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<0.05). Values in parentheses are percent increases or decreases. 
 
6
3
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CaV2.2 and producing a phosphoform that enhances Ca
2+
-dependent neurotransmitter 
release. (Bourinet et al., 1992; Stea et al., 1995).  
Conversely, we observed under steady-state conditions, that the inactive form of 
PMA, 4α-PMA, had no significant effect on transient peak current.  This confirms 
previous studies showing that 4α-PMA does not activate PKC under steady-state 
conditions (Castagna et al., 1982; Stea et al., 1995; García-Ferreiro et al., 2001) 
 
3.2.2 Steady-state Gating Kinetics 
Apparent phosphorylation of CaV2.2 by PMA-activated PKC induced a slowing 
of activation under steady-state depolarization at the end of a 10 min treatment but there 
was no change in activation rate at 4 min post treatment when we observed the maximal 
effect of PMA on transient peak current.  This increase of activation taus following PMA 
treatment indicates that phosphorylated CaV2.2 takes more time to open than the 
unphosphorylated channel. The increase in activation tau observed at 10 min post 
treatment in the presence of PMA was not observed in the presence of DMSO or 4α-PMA 
at either the 4 or 10 min post treatments. This slowing of activation tau in the presence of 
PMA indicates that phosphorylated CaV2.2 opens at a slower rate than unphosphorylated 
CaV2.2. This slowing of the time it takes for the channel to open would, in an in vivo 
neuron would decrease Ca
2+
 influx and decrease subsequent Ca
2+
-dependent 
neurotransmitter release.   
Inactivation taus were measured from peak current to end of protocol and are an 
indication of how fast or slow CaV2.2 closes under depolarizing conditions.  Inactivation 
taus of phosphorylated CaV2.2 significantly decreased at 4 min post treatment, indicating  
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Table 6. The effects of DMSO, PMA and 4α-PMA on CaV2.2 voltage-dependent activation and deactivation taus. 
   
An open diamond (◊) indicates significant difference from no treatment. A closed diamond (♦) indicates significant difference 
from DMSO. A closed circle (●) indicates significant difference from PMA. (n) indicates percent increase or decrease. 
Student’s T-test (P <0.05).
6
5
 
Treatment          
(10
-7
 M)
slope                    
(mV
-1 
± SEM)
y-intercept slope                    
(mV
-1 
± SEM)
y-intercept
No Treatment -0.023 ± 0.001 0.890 ± 0.026 0.012 ± 0.001 1.340 ± 0.074
DMSO -0.022 ± 0.001 0.944 ± 0.012 0.011 ± 0.002 1.359 ± 0.109
PMA -0.023 ± 0.001 1.031 ± 0.020 0.020 ± 0.002   
♦(45)
2.011 ± 0.104   
♦(32)
4α-PMA -0.019 ± 0.001 
♦(-14) ●(-17)
0.804 ± 0.012   
♦(-15) ●(-22)
0.007 ± 0.004   
●(-65)
1.087 ± 0.262   
●(-45)
DMSO -0.020 ± 0.001 0.951 ± 0.013       
◊(7)
0.012 ± 0.002 1.399 ± 0.106
PMA -0.022 ± 0.001 1.171 ± 0.017      
♦(23) 
0.023 ± 0.002  
♦(85)
2.315 ± 0.106 
♦(65)
4α-PMA -0.013 ± 0.001 
♦(-35) ●(-41)
0.737 ± 0.024       
♦(-22) ●(-37)
0.007± 0.005  
●(-70)
1.182 ± 0.311     
●(-49)
4 min 
10 min 
ηdeactvationηactvation
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that the phosphorylated channel takes less time to inactivate than the unphosphorylated 
channel. At 10 min post treatment, we did not observe a significant difference in average 
inactivation taus between phosphorylated and unphosphorylated CaV2.2. A decrease in 
average inactivation taus means that phosphorylated CaV2.2 takes less time to inactivate 
than unphosphorylated CaV2.2. This decrease in inactivation taus is not consistent with 
increased Ca
2+
 influx and neurotransmitter release observed in PMA-treated neuronal 
preparations because a fast inactivating channel does not allow for more Ca
2+
 to enter the 
cell.   
The significant and pronounced increase in average steady-state deactivation taus 
of phosphorylated CaV2.2 is consistent with the data that shows increased Ca
2+
 influx and 
neurotransmitter release in in vivo neuron preparations when treated with PMA (Swartz, 
1993; Zhu and Ikeda, 1994; García-Ferreiro et al., 2001). The larger the deactivation taus, 
the more time it takes for CaV2.2 to close after the removal of membrane depolarization 
and the greater the influx of Ca
2+ 
and neurotransmitter release. Phosphorylated CaV2.2 
takes longer to deactivate than unphosphorylated CaV2.2.  We know that endogenous 
CaV2.2 in in vivo neurons and synaptosomes undergo post translational modifications that 
include phosphorylation. The addition of deltamethrin to rat brain synaptosomes resulted 
in an increase in Ca
2+
 influx and subsequent neurotransmitter release.  We expect that the 
addition of deltamethrin to phosphorylated CaV2.2 expressed in Xenopus oocytes would 
result in an even greater increase in Ba
2+
 influx that is similar to what was observed when 
synaptosomes were treated with deltamethrin and Ca
2+
 enters the synaptosomes.  
Fang et al. (2006) demonstrated that there are several residues on CaV2.2 α-
subunit that regulate current in the presence of PMA.  CaV2.2 mutant S425A had  
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Table 7. The effects of DMSO, PMA and 4α-PMA on voltage-dependent deactivation (ηdeactivation). 
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-80 -70 -60 -50 -40 -30
Treatment    
(10
-7
M)
No Treatment 1.53 ± 0.16 1.66 ± 0.13 1.82 ± 0.10 2.02 ± 0.08 2.26 ± 0.08 2.56 ± 0.11
DMSO 1.81 ± 0.21 1.94 ± 0.19 2.10 ± 0.17 2.30 ± 0.16 2.55 ± 0.15 2.85 ± 0.17
PMA 1.64 ± 0.21 1.89 ± 0.15 2.24 ± 0.14 2.69 ± 0.20 3.28 ± 0.32   
♦(29)
4.03 ± 0.48 
♦(41)
4α-PMA 2.08 ± 0.66 2.08 ± 0.53 2.11 ± 0.40 2.17 ± 0.28 2.27 ± 0.15 2.41 ± 0.05    
●(-40)
DMSO 1.86 ± 0.23 2.03 ± 0.21 2.23 ± 0.20 2.46 ± 0.19 
◊(22)
2.74 ± 0.19 
◊(21)
3.07 ± 0.19 
◊(20)
PMA 1.65 ± 0.09 2.08 ± 0.13 2.62 ± 0.19 3.31 ± 0.27 
♦(44)
4.20 ± 0.38 
♦(65)
5.32 ± 0.54 
♦(86)
4α-PMA 2.5 ± 0.88 2.48 ± 0.75 2.49 ± 0.62 2.53 ± 0.49 2.60 ± 0.36 2.72 ± 0.23
Test Potential (mV)
4 min 
10 min 
taudeactivation (ms)
 68 
 
An open diamond (◊) indicates significant difference from no treatment. A closed diamond (♦) indicates significant difference 
from DMSO. A closed circle (●) indicates significant difference from PMA. Statistical differences were determined using 
Student’s T-test (P <0.05). Values in parentheses are percent increases or decreases.
6
8
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enhanced currents in the presence of PMA. CaV2.2 currents decreased in the presence of 
the unchanged S425 isoform. Although they did not show the effect of PMA on the 
kinetics of mutant forms of CaV2.2, we would expect that the kinetic profile of S425A 
CaV2.2 would be similar to PMA-treated CaV2.2. Some phosphorylation sites had more 
of an effect on peak current than others when phosphorylated. Phosphorylated S425 
decreased peak current, whereas phosphorylated T422 increased peak current.  Even in 
the presence of a S425A mutation, significant PMA enhancement of peak current occurs 
in the presence of not only phosphorylated T422 but phosphorylated S2108 as well.  The 
findings show us that it is not just one phosphorylation site or the other that increases or 
decreases CaV2.2 current, but multiple phosphorylation sites work together to effect 
changes in the response of CaV2.2 to changes in membrane potential.  The selective 
phosphorylation of these sites, alone and in combination, will be necessary in 
determining which sites, when phosphorylated, change the kinetic profile of CaV2.2. 
 
 
3.2.3 Voltage-dependent peak current 
Voltage-dependent peak current of phosphorylated CaV2.2 increased significantly 
at both the 4 and 10 min post treatments. A similar effect has been previously reported in 
the literature (Stea et al., 1995) and is consistent with enhanced Ca
2+
 influx and 
neurotransmitter release. Voltage-dependent peak current of phosphorylated CaV2.2 also 
underwent a 10 mV hyperpolarizing shift from 10 mV to 0 mV. This shift means that 
under phosphorylating conditions, 50% of the channels are opening at lower levels of 
membrane depolarization than they would have in their unphosphorylated state.  
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Unlike under steady-state depolarization, voltage-dependent peak current in the 
presence of 4α-PMA is significantly increased compared to our No Treatment control. 
This was an unexpected result given that 4α-PMA is considered an inactive analog to 
PMA and has no effect on CaV2.2 peak current under steady-state conditions presented 
here and elsewhere (Stea et al., 1995; Barrett and Rittenhouse, 2000; García-Ferreiro et 
al., 2001). The effect of 4α-PMA on CaV2.2 voltage-dependent peak current, however, is 
not significantly different from the effect of PMA on voltage-dependent peak current. 
Thus, it is possible, that the increase in voltage-dependent peak current observed in the 
presence of 4α-PMA may be due to differential phosphorylation of PKC activity. It is 
possible that 4α-PMA does activate PKC, but the spectrum of phosphorylation activity of 
4α-PMA-activated PKC may not be as broad as PMA-activated PKC would be. For 
example, S425 on the I-II intramembrane loop has been reported to down regulate CaV2.2 
activity when phosphorylated and 4α-PMA-activated PKC could be selectively not 
phosphorylating S425. Another possibility could be that 4α-PMA-activated PKC could be 
selectively phosphorylating T422, a site that has been shown to increase voltage-
dependent peak current (Fang et al., 2006; Symington et al., 2007a). 
 
3.2.4 Voltage-dependent Gating Kinetics 
The V50acts of phosphorylated CaV2.2 were not significantly different from the 
DMSO solvent control. We expected that with increases in Ba
2+
 influx via 
phosphorylated CaV2.2, the V50act would be hyperpolarized.  A hyperpolarized channel 
means that 50% of the channels will activate at depolarization levels lower than 
unphosphorylated CaV2.2 thus making the channel more sensitive to changes in 
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membrane potential.  
Significantly hyperpolarized V50inacts in the presence of PMA indicate that CaV2.2 
was more sensitive to undergoing inactivation at smaller changes in membrane potential.  
The increased sensitivity to small changes in membrane potential is inconsistent with 
increase neurotransmitter release observed when nerve cell preparations are treated with 
PMA (Stea et al., 1995; García-Ferreiro et al., 2001). Our data is consistent, however, 
with a previous study in which PMA caused a significant 20 mV hyperpolarizing shift in 
V50inact (we reported a significant 19 mV shift compared to DMSO control) (García-
Ferreiro et al., 2001). 
We have reported the average voltage-dependent rate of activation (ηactivation) of 
non-treated CaV2.2 to be 3.10 ± 0.15 ms at 10 mV. This ηactivation at is nearly identical with 
the ηactivation reported by Lin et al. (1997) using heterologous expression of CaV2.2 in 
Xenopus oocytes. The presence of PMA or 4α-PMA did not have a significant effect on 
the rates of activation (ηactivation) at 4 min post treatment in the range of -30 mV to 30 mV 
indicating that the voltage-dependent rates of activation neither increased nor decreased 
at this time (Table 5). However, at 10 min post treatment, PMA caused a significant 
increase in ηactivation at -20 mV, -10 mV, 0 mV, 10 mV, 20 mV and 30 mV compared to 
DMSO.  These increases in ηactivation mean that phosphorylated CaV2.2 was taking more 
time to activate under as the channel underwent increasing levels of depolarization. The 
22% increase in ηactivation means that it took CaV2.2 22% longer to activate when 
phosphorylated.  Compared to the presence of PMA at 10 min post treatment, 4α-PMA 
treated CaV2.2 produced a channel that activated at a faster rate, which was, as expected, 
not significantly different compared to the DMSO control.  
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We observed that under steady-state depolarization, phosphorylated CaV2.2 
required more time to activate at 10 min post treatment. Similarly, we have shown that 
ηactivation of phosphorylated CaV2.2 also increases significantly at 10 min post treatment 
and the time required to activate the channel remains significantly greater than the time 
required to activate unphosphorylated CaV2.2 under voltage-dependent conditions in the 
range of -20-30mV.  
Steady-state inactivation for phosphorylated CaV2.2 was not significantly altered 
compared to steady-state inactivation of unphosphorylated CaV2.2. Here, we see that 
phosphorylated CaV2.2 is activating slower and the slowing of activation remains at 
increasing levels of depolarization, phosphorylated CaV2.2 does not take longer to 
inactivate.  This slowing rate of activation and the unchanged rate of inactivation under 
phosphorylating conditions does not support the observation that phosphorylation 
increases Ba
2+
 and that the addition of PMA to neuronal cell cultures enhances Ca
2+
 
influx. Thus, we can conclude that phosphorylation of CaV2.2 does not increase Ba
2+
 or 
Ca
2+
 through activation or inactivation gating kinetics of the channel.    
In the presence of PMA, ηdeactivation was prolonged at 4 min post treatment at -40 
mV and -30 mV (Table 7). This prolongation of the time it takes for CaV2.2 to close after 
the removal of the membrane depolarization pulse corresponds with increased Ca
2+
 influx 
and neurotransmitter release because more Ca
2+
 is able to flow through the channel in the 
time it takes for it to completely deactivate.  Although ηdeactivation increased in the presence 
DMSO at 10 min post treatment at -50 mV, -40 mV and -30 mV compared to  no 
treatment, PMA still further increased ηdeactivation significantly more than the effect of 
DMSO at the same potentials.  The increase in ηdeactivation at -50 mV, -40 mV, and -30 mV 
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means that CaV2.2 is taking more time to deactivate at higher levels of depolarization, 
allowing more Ca
2+
 to influx, in the in vivo neuron would correspond to an increase in 
neurotransmitter release.   
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CHAPTER 4 
EFFECTS OF DELTAMETHRIN ON PMA-ACTIVATED PKC-PHOPHORYLATED 
CAV2.2 
 
4.1 Results 
 
4.1.1 Transient Peak Current 
Using the Transient
 
Test Protocol, maximal effects on transient peak current were 
observed for wild type CaV2.2 in the presence of deltamethrin, PMA + deltamethrin, and 
4α-PMA + deltamethrin during a 10 min incubation period (Fig. 8A).  The presence of 
deltamethrin significantly reduced transient peak current compared to the effect of 
DMSO at 4 min (-18%) and 10 (-29%) min post treatment. The presence of PMA + 
deltamethrin significantly increased transient peak current compared to DMSO by 69% at 
4 min and 82% at 10 min post treatment.  
The presence of PMA + deltamethrin significantly increased transient peak 
current by 107% at 4 min and 156% at 10 min post treatment compared to the effect of 
deltamethrin (Fig 8A). At 4 min post treatment, transient peak current in the presence of 
4α-PMA + deltamethrin was significantly less (-42%) than transient peak current in the 
presence of PMA + deltamethrin, but was significantly greater (19%) than transient peak 
current in the presence of deltamethrin alone. At 10 min post treatment, the effect of 4α-
PMA + deltamethrin on peak current was 47% less than the effect of PMA + 
deltamethrin. 
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Figure 8.  The effects of 0.1 % DMSO, deltamethrin (2 x 10
-7 
M), PMA (8 x 10
-7
 M) + 
deltamethrin (2 x 10
-7 M) and 4α-PMA (8 x 10-7 M) + deltamethrin (2 x 10-7 
M) on transient peak current of wild type CaV2.2 over a 10 min incubation 
period.  Significance was calculated using one-way ANOVA with Bonferroni’s 
multiple comparison post test (P<0.05). A diamond (♦) indicates significant 
difference from DMSO treatment.  A square (■) indicates significant 
difference from deltamethrin treatment. A circle (●) indicates significant 
difference from PMA treatment. The numbers of eggs (n) used for these 
treatments are as follows: DMSO (39); deltamethrin (18); PMA + 
deltamethrin (9); 4α-PMA + deltamethrin (10).  
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4.1.2 Steady-state Gating Kinetics 
In the presence of deltamethrin, steady-state activation taus were not significantly 
different from the DMSO controls at either the 4 min (Fig. 4A) or 10 min (Fig. 4B) post 
treatments. At 4 min post treatment, the PMA + deltamethrin treatment had no significant 
effect on activation taus compared to DMSO. The presence of PMA + deltamethrin 
significantly increased activation taus at 10 min post treatment (Fig 9B) compared to the 
effects of DMSO (27%) and deltamethrin (28%) (Table 8). The presence of 4α-PMA + 
deltamethrin had no significant effect on activation taus at either the 4 min or 10 min post 
treatments.   
Steady-state inactivation taus were not significantly changed in the presence of 
deltamethrin following either 4 min (Fig. 9C) or 10 min (Fig. 9D) post treatments. At 4 
min post treatment, average steady-state inactivation taus were significantly reduced by 
53% in the presence of PMA + deltamethrin compared to DMSO and reduced by 52% 
compared to deltamethrin (Fig. 9D). In the presence of PMA + deltamethrin, steady-state 
inactivation taus were not significantly different from DMSO or PMA (Table 3) at 10 min 
post treatment, but were significantly less than steady-state inactivation taus in the 
presence of deltamethrin by 62% (Table 6).  
 There were no significant effects of deltamethrin on steady-state deactivation taus 
following either 4 min or 10 min post treatments compared to DMSO (Fig. 9E and F). At 
4 and 10 min post treatment, the presence of PMA + deltamethrin significantly increased 
average deactivation taus by 79% and 54%, respectively, compared to DMSO (Fig. 9E).  
Although the difference in deactivation taus in the presence of PMA (Table 3) and PMA + 
deltamethrin were not significantly different at 4 min post treatment, the effect of PMA +  
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Figure 9.  The effects of 0.1 % DMSO, deltamethrin (2 x 10
-7
 M),  PMA (8 x 10
-7
 M) + 
deltamethrin (2 x 10
-7
 M) and 4α-PMA (8 x 10-7 M) + deltamethrin (2 x 10-7 
M) on steady-state kinetics of wild type CaV2.2 at 4 min and 10 min post 
treatment. Activation (A and B), inactivation (C and D) and deactivation (E 
and F) taus were normalized to their respective No Treatment controls. The 
number of eggs (n) used for activation and deactivation taus at 4 min post 
treatment were DMSO (38); deltamethrin (25) PMA + deltamethrin (10); 4α-
PMA + deltamethrin (9). The number of eggs (n) used for inactivation tau 
were DMSO (16); deltamethrin (19) PMA + deltamethrin (10); 4α-PMA + 
deltamethrin (9). Significance was determined by one-way ANOVA with 
Bonferroni’s multiple comparison post test (P <0.05).  Symbols followed by 
asterisks (*) indicate that P <0.1. 
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deltamethrin on deactivation taus was greater than the effect of PMA (Table 3). 
Deactivation taus in the presence of 4α-PMA+ deltamethrin at 4 min post treatment were 
37% less than the effect of PMA + deltamethrin but deactivation taus were not 
significantly altered at 10 min post treatment.  
 
4.1.3 Voltage-dependent Peak Current 
The presence of deltamethrin caused significant decrease (-12%) in maximal 
voltage-dependent peak current compared to No Treatment at 10 min post treatment (Fig. 
10B and Table 9). However, the decrease in maximal voltage-dependent peak current in 
the presence of deltamethrin was not significantly different from DMSO treatment at 10 
min post treatment (Table 9). The presence of PMA + deltamethrin significantly increased 
maximal voltage-dependent peak current compared to No Treatment (47%), DMSO 
treatment (70%) and deltamethrin (46%) at 4 min post treatment.   At 10 min post 
treatment, maximal voltage-dependent peak current in the presence of PMA + 
deltamethrin was reduced by -26% compared to the maximal peak current at 4 min post 
treatment. Compared to DMSO treatment at 10 min post treatment (Fig. 4), maximal 
voltage-dependent peak current in the presence of PMA + deltamethrin was significantly 
greater by 21%. The presence of 4α-PMA + deltamethrin significantly reduced maximal 
voltage-dependent peak current at 4 min post treatment by -16% compared to No 
Treatment and by -32% compared to 4α-PMA treatment. Maximal voltage-dependent 
peak current in the presence of 4α-PMA + deltamethrin was significantly less than the 
effect of PMA + deltamethrin treatment at 4 min post treatment by -43%. At 10 min post 
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Table 8. The effects of DMSO, deltamethrin, PMA + deltamethrin and 4α-PMA + deltamethrin on CaV2.2 steady-state transient 
peak current, activation, inactivation and deactivation taus.    
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DMSO Deltamethrin
PMA + 
deltamethrin
4α-PMA + 
deltamethrin
Transient Peak Current 
(μAT/μANT x 100)
106.6 ± 3.2 87.4 ± 5.1      
♦(-18)
180.6 ± 15.3         
♦(69) ■(107)
104.2 ± 5.0         
●(-42) ■(19)
Activation tau (η)         
(msecT/msecNT x 100)
108.4 ± 1.8 100.9 ± 4.2 101.3 ± 3.8 102.7 ± 3.4
Inactivation tau (η) 
(msecT/msecNT x 100)
124.1 ± 12.5 123.8 ± 10.7 58.8 ± 6.5         
♦(-53) ■(-52)
97.2 ± 11.2
Deactivation tau (η) 
(msecT/msecNT x 100)
104.0 ± 6.6 125.6 ± 13.9 186.5 ± 42.5        
♦*(79)
102.5 ± 5.1      
□(-37)
Transient Peak Current 
(μAT/μANT x 100)
102.1 ± 4.5 72.6 ± 15.8        
♦(-29) 
185.8 ± 5.6              
♦(82) ■(156)
97.7 ± 9.1        
●(-47)
Activation tau (η) 
(msecT/msecNT x 100)
108.4 ± 1.8 107.7 ± 4.3 135.8 ± 15.3       
♦(27) ■(28)
105.5 ± 5.4
Inactivation tau (η) 
(msecT/msecNT x 100)
166.3 ± 32.5 243.7 ± 40.8 92.8 ± 12.5     
■(-62)
198.7 ± 52.5
Deactivation tau (η) 
(msecT/msecNT x 100)
104.0 ± 6.6 129.6 ± 15.3 160.3 ± 17.2    
♦*(54)
100.6 ± 6.3
Treatment (10
-7
 M)
4 min 
10 min
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All values are normalized to the no treatment control (100.0). A closed diamond (♦) indicates significant difference from 
DMSO. A closed square (■) indicates significant difference from deltamethrin. A closed circle (●) indicates significant 
difference from PMA. An open square (□) indicates significant difference from PMA + deltamethrin. The values in parentheses 
(n) are percent increases or decreases. Significance was determined by One-way ANOVA with Bonferroni’s multiple 
comparison post test (P <0.05). Asterisks (*) indicates the P < 0.10. 
9
8
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treatment, deltamethrin treatment caused a significant -12% reduction in peak current 
compared to No Treatment, but the effect was not significantly different from the effect 
of DMSO (Table 4). PMA + deltamethrin treatment increased maximal peak current by 
21% compared to DMSO. 4α-PMA + deltamethrin treatment significantly decreased peak 
current by -27% compared to No Treatment at 10 min post treatment.  Compared to PMA 
+ deltamethrin treatment at 10 min post treatment, 4α-PMA + deltamethrin treatment 
significantly reduced peak current by 33%. The presence of 4α-PMA + deltamethrin 
treatment significantly reduced peak current by -26% compared to 4α-PMA treatment at 
10 min post treatment.  
 
4.1.4 Voltage-dependent Gating Kinetics 
The Activation Protocol was used to measure the midpoint activation potential 
(V50act) in the presence of deltamethrin, PMA + deltamethrin and 4α-PMA + deltamethrin 
(Fig. 10C and D; Table 9). The presence of deltamethrin resulted in no significant effect 
on V50act compared to DMSO at either 4 or 10 min post treatments.  In the presence of 
PMA + deltamethrin, V50act underwent significant 56% and 117% hyperpolarizing shifts 
at 4 and 10 min post treatments, respectively compared to the V50act in the presence of 
PMA (Table 9). In the presence of 4α-PMA + deltamethrin at 4 min post treatment, 
significant depolarizing shifts in the V50act compared to DMSO (175%), deltamethrin 
(171%), and 4α-PMA (142%) (Table 9) were apparent. 
In the presence of deltamethrin at 4 and 10 min post treatment, there was no 
significant effect on the inactivation midpoint potential (V50inact) compared to DMSO 
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Figure 10.  Effects of 0.02% DMSO, deltamethrin (1 x 10
-7
 M), PMA (1 x 10
-7
 M) + 
deltamethrin (1 x 10
-7
 M) and 4α-PMA (1 x 10-7 M) + deltamethrin (1 x 10-7 
M) on voltage-dependent peak current, activation midpoint potential and 
inactivation midpoint potential at 4 min and 10 min post treatment. (A and B) 
Voltage-dependent peak current was normalized to the DMSO control (value 
of DMSO treatment normalized to 1). (C and D) Activation midpoint 
potentials and (E and F) inactivation midpoint potentials were determined by 
the least-squares fits of the current-voltage relationship from individual 
experiments of the Activation and Inactivation Test Protocols using the 
sigmoidal dose-response (variable slope) equation. Significance was 
calculated using Student’s T-test (P < 0.05). The number of eggs (n) used for 
A-D treatments are DMSO (19); deltamethrin (5); PMA + deltamethrin (5); 
4α-PMA + deltamethrin (5). (E and F) The number of eggs (n) used for E-F 
treatments are DMSO (12); deltamethrin (5); PMA + deltamethrin (5); 4α-
PMA + deltamethrin (5). Significance was calculated using Student’s T-test 
(P<0.05). 
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(Table 9). The presence of PMA + deltamethrin at 4 min post treatment caused a 
hyperpolarizing shift in the V50inact that was significantly different from both DMSO 
(28%) and deltamethrin (71%). At 10 min post treatment, the presence of PMA + 
deltamethrin caused a significant 63% hyperpolarizing shift in V50inact compared to 
DMSO and a significant 111% hyperpolarizing shift in V50inact compared to PMA. The 
presence of 4α-PMA + deltamethrin caused a significant 29% depolarizing shift in V50inact 
compared to DMSO at 4 min post treatment. 
Voltage-dependent rate constants for activation (ηactivation) are shown in Table 10. 
Deltamethrin treatment resulted in no significant effect on ηactivation at either 4 or 10 min 
post treatment compared to DMSO. PMA + deltamethrin treatment resulted in no 
significant effect compared to DMSO at 4 min post treatment. However, PMA + 
deltamethrin significantly increased ηactivation by 33% (-20 mV), 28% (-10 mV), 20% (0 
mV), 23% (10 mV) 21% (20 mV) and 20% (30 mV), respectively, at 10 min post 
treatment compared to the DMSO. The presence of deltamethrin on 4α-PMA-treated 
CaV2.2 had the unexpected effect of significantly increasing ηactivation at-30 mV by 90% 
and at -20 mV and -10 mV by 33% compared to DMSO. At -30 mV, the 4α-PMA + 
deltamethrin treatment increased ηactivation by 67% compared to deltamethrin alone.  
ηactivation in the presence of 4α-PMA + deltamethrin was significantly less than ηactivation in 
the presence of PMA + deltamethrin at 20 mV and 30 mV by 16% and 21%, respectively.   
At 4 min post treatment, ηactivation slope in the presence of deltamethrin was not 
significantly different from DMSO (Fig. 11A). The ηactivation slope at 10 min post 
deltamethrin treatment, however, was significantly increased by 30% compared to 
DMSO control (Fig. 11C and Table 11). In the presence of PMA+ deltamethrin at 4 min 
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Table 9. The effects of DMSO, deltamethrin, PMA + deltamethrin and 4α-PMA + deltamethrin on voltage-dependent peak 
current, activation and inactivation midpoint potentials.   
 
An open diamond (◊) indicates significant difference from No Treatment. A closed diamond (♦) indicates significant difference 
from DMSO. A square (■) indicates significant difference from deltamethrin. A circle (●) indicates significant difference from 
PMA. A triangle (Δ) indicates significant difference from 4α-PMA. A open circle (○) indicates significant difference from 
PMA + ΔM.  The values in parentheses (n) are percent increases or decreases. Significance was calculated using Student’s T-
1
0
3
 
No Treatment DMSO Deltamethrin
PMA + 
deltamethrin
4α-PMA + 
deltamethrin
4 min 
Voltage-dependent 
peak current
-0.99 ± 0.01 -0.86 ± 0.07         
◊(-12%)
-1.00 ± 0.04 -1.46 ± 0.19 
◊(47) ♦(70) 
■*(46)
-0.83 ± 0.08                               
◊(-16) ○*(-43)          
Δ*(-32)
Activation MPP          
(mV ± SEM)
-1.47 ± 0.33 -1.71 ± 0.65 -1.83 ± 0.35 -2.09 ± 0.29       
●(-56)
1.30 ± 0.61                    
♦(175) ■(171) 
Δ(142)
Inactivation MPP                
(mV ± SEM)
-27.35 ± 5.01 -34.38 ± 2.34 
◊(25)
-25.73 ± 2.47 -44.07 ± 3.45         
♦(-28) ■(-71)
-24.55 ± 3.06         
♦(29)
10 min 
Voltage-dependent 
peak current
-0.99 ± 0.01 -0.64 ± 0.07 
◊(-35)
-0.87 ± 0.05 
◊(-12)
-1.08 ± 0.17 
♦(21)
-0.72 ± 0.08                 
◊(-27) ○*(-33)            
Δ(-26)
Activation MPP        
(mV ± SEM)
-1.47 ± 0.33 -0.22 ± 0.74    
◊(88)
-3.44 ± 0.69 -3.04 ± 0.61        
●(-117)
0.85 ± 0.72               
■(124)
Inactivation MPP      
(mV ± SEM)
-27.02 ± 1.10  -28.79 ± 0.67  -21.21 ± 2.16 -44.69 ± 1.56           
♦(-63) ■(-111)
-20.07 ± 0.79
Treatment (10
-7
 M)
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test (P<0.05). Symbols followed by an asterisk (*) indicate that the significance level was P < 0.1. 
1
0
4
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post treatment, ηactivation slope was reduced by 14% compared to DMSO. 4α-PMA + 
deltamethrin treatment significantly reduced ηactivation slope by 35% compared to DMSO 
and by 38% compared to deltamethrin at 10 min post treatments. 
Deltamethrin and PMA + deltamethrin treatments resulted in no significant effects 
on ηactivation y-intercept of CaV2.2 at 4 min post treatment but PMA + deltamethrin 
treatment significantly increased the ηactivation y-intercept compared to DMSO by 23% at 
10 min post treatment. The ηactivation y-intercept was significantly reduced (-16%) by the 
4α-PMA + deltamethrin treatment compared to DMSO at 4 min post treatment.   
The 4 min deltamethrin treatment caused a significant increase (15%) in the 
voltage-dependent rate constant for deactivation (ηdeactivation) at -30 mV (Table 12).  At 10 
min post deltamethrin treatment, there was no effect on ηdeactivation. PMA + deltamethrin 
treatment also produced no significant effect on ηdeactivation at either 4 or 10 min post 
treatment. The 4 min post 4α-PMA + deltamethrin treatment caused significant 
reductions in ηdeactivation values at -60 mV (40%), -50 mV(32%), -40 mV(35%) and -30 
mV (36%) compared to their respective DMSO ηdeactivation  values. The 10 min post 4α-
PMA + deltamethrin treatment, also reduced the ηdeactivation values by 43% (-60 mV), 36% 
(-50 mV), 39% (-40 mV) and 41% (-30 mV). Deltamethrin had no significant effect on 
ηdeactivation slope at either the 4 or 10 min post treatments compared to DMSO (Table 11). 
The effect of PMA + deltamethrin on ηdeactivation slope was significantly reduced by 50% 
compared to PMA at 4 min post treatment and by 30% at 10 min post treatment (Table 
11). 
Deltamethrin and PMA + deltamethrin resulted in no significant effects on the 
ηdeactivation y-intercepts at either 4 or 10 min post treatments compared to DMSO. The 
  106 
Figure 11.  Semi-logarithmic plots of the activation tau (ηactivation) and deactivation tau 
(ηdeactivation) values resulting from the effects of DMSO, deltamethrin (1 x 10
-7
 
M), PMA (1 x 10
-7
 M) + deltamethrin (1 x 10
-7
 M) and 4α-PMA (1 x 10-7 M) 
+ deltamethrin (1 x 10
-7
 M) + at 4 min (A and B) and 10 min (C and D) post 
treatment using the Activation Protocol (A and C) and the Deactivation 
Protocol (B and D), respectively. Activation tau and deactivation tau rate 
constants were obtained from linear regression fits to the data. The number 
of eggs (n) used for panels A and C are DMSO (n = 18); deltamethrin (n = 
5); PMA + deltamethrin (n = 5); 4α-PMA + deltamethrin (n = 5). The 
number of eggs (n) used for panels B and D are DMSO (n = 18); 
deltamethrin (n = 5); and PMA + deltamethrin (n = 5); 4α-PMA + 
deltamethrin (n = 5). Significance was calculated using Student’s T-test 
(P<0.05). 
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ηdeactivation y-intercept was reduced by 31% following the 4 min PMA + deltamethrin 
treatment compared to PMA (Table 6). The effects of PMA + deltamethrin treatment on 
the ηdeactivation y-intercepts were significantly less (-38% at 4 min and 44% at 10 min) than 
DMSO.  4α-PMA + deltamethrin treatment significantly reduced ηdeactivation y-intercept 
compared to deltamethrin by at both 4 (-38%) and 10 min (-52%) min post treatments 
(Table 6).  
 
4.2 Discussion 
4.2.1. Transient peak current 
It is known that CaV2.2 undergoes post-translational modifications that include 
phosphorylation (Swartz, 1993; Swartz et al., 1993; Zhu and Ikeda, 1994). There are five 
sites located on the intracellular loops of CaV2.2 capable of being phosphorylated by 
PKC and it has been shown that, depending on which sites are phosphorylated, CaV2.2 
will exhibit different functional characteristics (Fang et al., 2006). When CaV2.2 is 
phosphorylated by PMA-activated PKC, there is no control over which of the available 
sites are phosphorylated. The uncertainty of which sites are actually phosphorylated or 
not may have produced different phosphoforms from those produced in the synaptosomes 
and  via mutagenesis and may have contributed to the different results obtained in the 
current study versus those obtained previously using different protocols (Symington and 
Clark, 2005; Symington et al., 2007a).  
Nevertheless, the current data support, in part, previous findings, which suggest 
that deltamethrin modifies phosphorylated CaV2.2 and increases channel conductance. 
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Table 10. The effects of DMSO, deltamethrin, PMA + deltamethrin and 4α-PMA + deltamethrin on voltage-dependent activation 
(ηactivation). 
 
1
0
9
 
-30 -20 -10 0 10 20 30
Treatment      
(10
-7
M)
No Treatment 5.05 ± 0.41 3.93 ± 0.24 3.10 ± 0.15 2.46 ± 0.09 1.97 ± 0.07 1.58 ± 0.06 1.28 ± 0.05
DMSO 5.09 ± 0.28 4.08 ± 0.20 3.27 ± 0.14 2.64 ± 0.10 2.13 ± 0.07 1.73 ± 0.06 1.41 ± 0.05
Deltamethrin 4.80 ± 0.36 3.90 ± 0.25 3.17 ± 0.17 2.58 ± 0.12 2.10 ± 0.09 1.72 ± 0.08 1.40 ± 0.08 
◊(10)
PMA + 
deltamethrin
4.75 ± 0.39 3.96 ± 0.29 3.30 ± 0.21 2.75 ± 0.15 2.30 ± 0.11 1.92 ± 0.09 1.60 ± 0.07
4α-PMA + 
deltamethrin
4.38 ± 0.41 3.63 ± 0.25 3.02 ± 0.15 2.52 ± 0.09 2.10 ± 0.09 1.76 ± 0.11 1.48 ± 0.13
DMSO 4.78 ± 0.24 3.91 ± 0.17 3.20 ± 0.13 2.62 ± 0.10 2.15 ± 0.08 1.77 ± 0.07 1.46 ± 0.06
Deltamethrin 5.42 ± 0.32 4.34 ± 0.21 3.47 ± 0.13 2.78 ± 0.08 2.23 ± 0.06 1.79 ± 0.06 1.44 ± 0.06
PMA + 
deltamethrin
5.07 ± 0.53 5.19 ± 0.99 
♦ (33)
4.11 ± 0.58 
♦(28)
3.28 ± 0.3 
♦(20)
2.64 ± 0.13 
♦(23) ■(18)
2.14 ± 0.03 
♦(21) ■(20)
1.75 ± 0.07 
♦(20) ■(22)
4α-PMA + 
deltamethrin
9.07 ± 2.31 
♦(90) ■(67)
5.83 ± 1.24 
♦(33)
4.26 ± 0.71 
♦(33)
3.16 ± 0.37 2.36 ± 0.16 1.79 ± 0.06 
□(-16)
1.38 ± 0.09 
□(-21)
Test Potential (mV)
tauactivation (ms)
4 min 
10 min 
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An open diamond (◊) indicates significant difference from No Treatment.  A closed diamond (♦) indicates significant difference 
from DMSO.  A square (■) indicates significant difference from deltamethrin.  An open square (□) indicates significant difference 
from PMA + deltamethrin.  The values in parentheses (n) are percent increases or decreases. Significance was calculated using 
Student’s T-test (P<0.05). 
1
1
0
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As expected, when deltamethrin was applied to heterologously expressed 
unphosphorylated wild type CaV2.2 under steady-state conditions, peak current 
decreased. This finding was the same as that initially reported by Symington and Clark 
(2005). When deltamethrin was applied to CaV2.2 that had been phosphorylated in a 
PMA-activated PKC-dependent manner under steady-state conditions, however, peak 
current significantly increased (Alves et al., 2009).  
The decrease in peak CaV2.2 current observed when deltamethrin was applied to 
unphosphorylated CaV2.2 was inconsistent with biochemical studies which showed that 
dosing with deltamethrin significantly increased neurotransmitter release from rat brain 
synaptosomes (Symington et al., 2007b). Dosing live rats with deltamethrin also 
increased neurotransmitter release (Aldridge et al., 1978; Hossain et al., 2004). The 
increase in neurotransmitter release was, therefore, consistent with the CS-syndrome 
observed during deltamethrin poisoning. The decrease in peak current caused by the 
dosing of deltamethrin on unphosphorylated CaV2.2 under steady state conditions is 
inconsistent with previous reports and led us to conclude that post translational 
modifications, which are not readily available in the non-neuronal Xenopus oocyte 
system, but are available in the in vivo system, may play a role in how deltamethrin acts 
upon the channel.  
A permanently phosphorylated channel was created by site-directed mutagenesis, 
which converted a threonine at site 422 (T422) to a glutamate (T422E). This permanently 
phosphorylated channel, when heterologously expressed in Xenopus oocytes and treated 
with deltamethrin, mimicked the effect of deltamethrin in the live rat in vivo system, and 
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Table 11. The effects of DMSO, deltamethrin, PMA+ deltamethrin and 4α-PMA + deltamethrin on the slopes and intercepts of 
CaV2.2 voltage dependent activation and deactivation taus. 
 
An open diamond (◊) indicates significant difference from No Treatment.  A closed diamond (♦) indicates significant 
1
1
2
 
Treatment          
(10
-7
 M)
slope                    
(mV
-1 
± SEM)
y-intercept slope                    
(mV
-1 
± SEM)
y-intercept
DMSO -0.022 ± 0.001 0.944 ± 0.012    
◊(6)
0.011 ± 0.002 1.359 ± 0.109
Deltamethrin -0.023 ± 0.002 0.905 ± 0.046 0.015 ± 0.002 1.630 ± 0.115
PMA + 
deltamethrin
-0.019 ± 0.001   
♦(14)
0.995 ± 0.026 0.010 ± 0.002    
●(-50)
1.381 ± 0.103   
●(-31)
4α-PMA + 
deltamethrin
-0.020 ± 0.001 0.794 ± 0.0180    
♦(-16)
0.008 ± 0.003 0.844 ± 0.180     
♦(-38) ■(-48)
DMSO -0.020 ± 0.001 0.951 ± 0.013       
◊(7)
0.012 ± 0.002 1.399 ± 0.106
Deltamethrin -0.026 ± 0.002     
♦(30)
0.987 ± 0.054    0.015 ± 0.002 1.630 ± 0.105
PMA + 
deltamethrin
-0.021 ± 0.001  
■(19)
1.168 ± 0.022 
♦(23) ■(18) 
0.016 ± 0.002 
●(-30)
1.770 ± 0.112  
●(-24)
4α-PMA + 
deltamethrin
-0.013 ± 0.001 
♦(-35) ■(-50)
0.763 ± 0.021         
♦(-20) ■(-23)
0.007 ± 0.004  0.784 ± 0.217   
♦(-44) ■(-52)
4 min 
10 min 
ηactvation ηdeactvation
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difference from DMSO.  A square (■) indicates significant difference from deltamethrin. A circle (●) indicates 
significant difference from PMA. The values in parentheses (n) are percent increases or decreases. Significance was 
calculated using Student’s T-test (P<0.05). 
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in intact synaptosomes by significantly increasing Ba
2+
(Ca
2+
), current (Symington et al., 
2007a). To observe the effects of deltamethrin on wild type CaV2.2 under 
phosphorylating conditions, PMA was used to induce endogenous PKC activity in the 
Xenopus heterologous expression system with the expectation that PKC phosphorylation 
activity would not be selective. Under steady-state depolarization, PMA + deltamethrin 
treatment significantly increased Ba
2+
 current compared to DMSO and deltamethrin 
treatments at both 4 and 10 min post treatment. The increase in peak current via PMA-
activated PKC-dependent phosphorylated CaV2.2 in the presence of deltamethrin 
supports the hypothesis that phosphorylation enhances the action of deltamethrin on 
CaV2.2.  
 
4.2.2 Steady-state Gating Kinetics 
Deltamethrin treatment produced no significant effect on steady-state activation of 
CaV2.2, but PMA + deltamethrin significantly increased activation taus at 10 min post 
treatment compared to DMSO and deltamethrin alone. The increase in steady-state 
activation taus indicates that phosphorylated CaV2.2, when treated with deltamethrin, is 
slow to activate completely causing a reduction in Ba
2+
 influx. This delay in activation is 
consistent with a study by Symington and Clark (2005), in which steady-state activation 
taus of CaV2.2 were significantly increased in the presence of deltamethrin. As expected, 
the treatment of 4α-PMA + deltamethrin resulted in no effect on steady-state activation. 
The reduction in Ba
2+
 (or Ca
2+
)
 
influx due to the slowing of steady-state activation 
of phosphorylated CaV2.2 activation in the presence of deltamethrin is not consistent with 
increased neurotransmitter release. When applied to synaptosomes, deltamethrin caused 
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Table 12. The effects of DMSO, deltamethrin, PMA + deltamethrin and 4α-PMA + deltamethrin on voltage-dependent 
deactivation (ηdeactivation). 
-80 -70 -60 -50 -40 -30
Treatment       
(10
-7
M)
No Treatment 1.53 ± 0.16 1.66 ± 0.13 1.82 ± 0.10 2.02 ± 0.08 2.26 ± 0.08 2.56 ± 0.11
DMSO 1.81 ± 0.21 1.94 ± 0.19 2.10 ± 0.17 2.30 ± 0.16 2.55 ± 0.15 2.85 ± 0.17
Deltamethrin 1.55 ± 0.12 1.8 ± 0.14 2.09 ± 0.16 2.43 ± 0.19 2.83 ± 0.22 3.29 ± 0.26 
♦(15)
PMA + 
deltamethrin
1.82 ± 0.17 1.99 ± 0.14 2.19 ± 0.10 2.42 ± 0.09 2.68 ± 0.14 2.98 ± 0.23
4α-PMA + 
deltamethrin
0.98 ± 0.05 1.11 ± 0.05 1.27 ± 0.06    
♦(-40)
1.57 ± 0.15 
♦(-32)
1.67 ± 0.09 
♦(-35)
1.80 ± 0.14 
♦(-36)
DMSO
1.86 ± 0.23 2.03 ± 0.21 2.23 ± 0.20 2.46 ± 0.19 
◊(22)
2.74 ± 0.19 
◊(21)
3.07 ± 0.19 
◊(20)
Deltamethrin 1.52 ± 0.08 1.77 ± 0.1 2.06 ± 0.13 2.41 ± 0.17 2.81 ± 0.22 3.28 ± 0.28
PMA + 
deltamethrin
1.62 ± 0.17 1.89 ± 0.15 2.22 ± 0.14 2.61 ± 0.15 3.08 ± 0.21 3.65 ± 0.33
4α-PMA + 
deltamethrin
 0.98 ± 0.05 1.11 ± 0.05 1.28 ± 0.06   
♦(-43)
1.57 ± 0.15 
♦(-36)
1.67 ± 0.09 
♦(-39)
1.80 ± 0.14 
♦(-41)
Test Potential (mV)
taudeactivation (ms)
10 min 
4 min 
1
1
5
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An open diamond (◊) indicates significant difference from No Treatment.  A closed diamond (♦) indicates significant 
difference from DMSO.  The values in parentheses (n) are percent increases or decreases. Significance was calculated 
using Student’s T-test (P<0.05). 
1
1
6
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an increase in neurotransmitter release and this cannot be achieved if neurotransmitter 
release is dependent on channel activation alone. Thus, we can conclude that steady-state 
activation is not the process by which deltamethrin alters CaV2.2 conductivity to increase 
Ca
2+
-dependent neurotransmitter release. 
Although not statistically significant, the rate of inactivation of unphosphorylated 
CaV2.2 was slowed in the presence of deltamethrin (Table 6). This slowing of inactivation 
is consistent with a previous report in which deltamethrin significantly slowing down the 
rate of  unphosphorylated CaV2.2 steady-state inactivation (Symington and Clark, 2005). 
PKC-phosphorylated CaV2.2 inactivates faster in the presence of deltamethrin when 
compared to the inactivation of unphosphorylated CaV2.2 in the presence of DMSO or 
deltamethrin. This reduction in steady-state inactivation taus indicates that 
phosphorylated CaV2.2 in the presence of deltamethrin takes less time to inactivate than 
its unphosphorylated form and reduces Ba
2+
 influx.  Because Ba
2+
 influx via CaV2.2 
under phosphorylating conditions was increased, we expected a slowing of inactivation 
may have occurred.  However, we observed a slowing of inactivation in the presence of 
deltamethrin only when CaV2.2 was not undergoing PMA-activated PKC 
phosphorylation.  When CaV2.2 is phosphorylated, we observed that deltamethrin 
significantly increased the rate at which the channel inactivated under steady-state 
depolarization. This finding is not consistent with increased Ca
2+
 influx necessary for 
increased neurotransmitter release. We can conclude from this data that, like steady-state 
activation, steady-state inactivation is not a process by which deltamethrin alters CaV2.2 
conductance to increase Ca
2+
-dependent neurotransmitter release. 
Steady-state deactivation in the presence of PMA + deltamethrin was significantly 
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increased at both 4 and 10 min post treatments. An increase in deactivation taus indicates 
a slower rate of open channels going to the closed state after the removal of steady-state 
membrane depolarization signal (voltage change). This slower rate of closure means that 
more Ba
2+
 is able to enter the cell via CaV2.2. Within the in vivo system, this increase in 
Ba
2+
 (or Ca
2+
) influx results in the increased release of neurotransmitters.  Furthermore, 
the increase in neurotransmitter release is consistent with the symptoms observed in CS-
syndrome as a result of deltamethrin poisoning (Hossain et al., 2004).   
4α-PMA was used to test how deltamethrin would affect channel kinetics in the 
presence of a phorbol ester that does not activate PKC-phosphorylation. When 
deltamethrin was applied to 4α-PMA-treated CaV2.2, deactivation taus were reduced. 
This reduction in deactivation taus means that 4α-PMA-treated CaV2.2 deactivates faster 
than untreated CaV2.2 in the presence of deltamethrin.  From this, we can conclude that 
deltamethrin alters CaV2.2 deactivation kinetics under phosphorylating conditions and 
that this change in deactivation gating kinetics increases Ba
2+
 influx. From this, we can 
infer that the addition of deltamethrin to the in vivo system would result in increased 
Ca
2+
-depedent neurotransmitter release that is consistent with CS-syndrome.  
The increase in transient peak current and the slowing of deactivation rates of 
phosphorylated CaV2.2, in the presence of deltamethrin, allow for increased Ba
2+
 influx 
via phosphorylated CaV2.2. Within the in vivo system, the increase in Ba
2+ 
(or Ca
2+
) 
influx would translate into to increased neurotransmitter release, an effect observed 
during deltamethrin poisoning.   
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4.2.3 Voltage-dependent peak current 
Deltamethrin treatment produced a significant decrease in maximal voltage-
dependent peak current at 10 min post treatment, which agrees with our steady-state data 
and previously reported results that deltamethrin reduces steady state and voltage-
dependent peak current (Symington and Clark, 2005). The decrease in peak current 
indicates that less Ba
2+
 is entering the cell via CaV2.2, which would translate into a 
decrease in Ca
2+
 influx and a decrease in neurotransmitter release in the in vivo neuron.   
We expected that the increase in peak current caused by PMA treatment would be 
augmented by the presence of deltamethrin due to the observation that deltamethrin 
increases neurotransmitter release from the in vivo neuron. We observed a significant 
increase in voltage-dependent peak current of phosphorylated CaV2.2 in the presence of 
deltamethrin. Within the in vivo neuron, this increase in peak current of phosphorylated 
CaV2.2 in the presence of deltamethrin would mean that a significantly greater amount of 
Ca
2+
 was flowing through the channel causing a significant increase in neurotransmitter 
release.   
In the presence of deltamethrin, the CaV2.2 mutant T422E underwent an increase 
in maximal voltage-dependent peak current, which mimicked the effect of deltamethrin in 
vivo (Symington et al., 2007a). We observed a similar increase in voltage-dependent peak 
current of phosphorylated CaV2.2 in the presence of deltamethrin but the actual 
phosphorylation pattern of CaV2.2 resulting from PMA-activated PKC phosphorylation 
under experimental conditions is unknown. Using site-directed mutagenesis it was 
determined that Ser425 is inhibitory when phosphorylated while the other four PKC-
dependent phosphorylation sites enhance Ba
2+
 influx (Fang et al., 2006). Our experiments 
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do not control for which phosphorylation sites on CaV2.2 are phosphorylated and which 
ones are not.  Therefore using site-directed mutagenesis , we can “phosphorylate” the 
channel at single or multiple sites by replacing the wild type amino acid with glutamate 
and determine under which phosphorylation patterns we observe an increase in Ba
2+
 
(Ca
2+
) influx in the presence of deltamethrin.    
Maximal peak current in the presence of 4α-PMA + deltamethrin decreased at 
both 4 and 10 min post treatment compared to No Treatment, 4α-PMA and PMA + 
deltamethrin. This reduction in peak current means that Ba
2+
 influx through 
unphosphorylated CaV2.2 in the presence is reduced. There was no significant difference 
between CaV2.2 peak current in the presence of deltamethrin and CaV2.2 peak current in 
the presence of 4α-PMA + deltamethrin indicating that the presence of the inactive 
phorbol ester does not change the action of deltamethrin on the channel.  
We propose that the difference between the effect of PMA + deltamethrin on 
steady-state peak current versus voltage-dependent peak current may be due the multiple 
step depolarizations that occur during the Activation Test Protocol used to obtain voltage-
dependent peak current versus the single step depolarization of the Transient Test 
Protocol. As CaV2.2 undergoes multiple step depolarizations, the channels that are 
opening at lower potentials are inactivating and remain in their unwilling state during 
subsequent depolarization steps. The inactivation of these channels may be a mechanism 
by which the maximal effect of deltamethrin on phosphorylated CaV2.2 during voltage-
dependent protocols was not observed.  
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4.2.4 Voltage-dependent Gating Kinetics 
Activation midpoint potentials (V50act) obtained in our study are consistent with 
previous findings of enhanced neurotransmitter release. The V50act of unphosphorylated 
CaV2.2 in the presence of deltamethrin underwent a hyperpolarizing shift at both 4 and 10 
min post treatments. Phosphorylated CaV2.2 treated with deltamethrin had a significantly 
greater hyperpolarizing shift in V50act compared to the V50act of the untreated 
phosphorylated channels, indicating that the activation of phosphorylated CaV2.2 
occurred at lower levels of depolarization. The increased sensitivity of deltamethrin-
treated PKC-phosphorylated CaV2.2 to smaller levels of membrane depolarizations is 
consistent with increased Ba
2+
 influx within our heterologous expression system, and 
enhanced neurotransmitter release within the in vivo system. In the presence of 4α-PMA 
+ deltamethrin, the V50act underwent a depolarizing shift making the channel less likely to 
activate when the membrane undergoes depolarization consistent with less Ba
2+
 (or Ca
2+
) 
influx and less neurotransmitter release.  
Deltamethrin treatment had no significant effect on inactivation midpoint 
potentials (V50inact) of unphosphorylated CaV2.2. In the presence of PMA+ deltamethrin, 
V50inact underwent a significant hyperpolarizing shift compared to the effects of DMSO 
and deltamethrin treatments. This hyperpolarizing shift indicates that CaV2.2 will 
inactivate at lower levels of depolarization thereby reducing the amount of Ba
2+
 influx. 
The reduction of Ba
2+
 (or Ca
2+
) influx would translate into reduced neurotransmitter 
release within the in vivo system. With the increase in neurotransmitter release observed 
by Symington et al. (2007a), we expected to observe a depolarizing shift in V50inact, which 
would indicate that CaV2.2 would require greater levels of depolarizations to inactivate. 
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Instead, a significant hyperpolarizing shift similar to what we observed in the presence of 
PMA was observed when phosphorylated CaV2.2 was treated with deltamethrin caused. 
Deltamethrin also had no effect on voltage-dependent activation rate constants of 
unphosphorylated CaV2.2 (ηactivation) following either the 4 or 10 min post treatments. The 
increase in ηactivation at 10 min post treatment in the presence of PMA + deltamethrin 
significantly increased at step potentials between -20 mV and 30 mV compared to DMSO 
and indicates that phosphorylated CaV2.2 took more time to activate in the presence of 
deltamethrin than the unphosphorylated channel. Also, the presence of deltamethrin on 
the phosphorylated channel caused an increase in the length of time required to activate 
the channel compared to the effect of deltamethrin on the unphosphorylated channel 
between 10 mV and 30 mV. The increase in ηactivation of phosphorylated CaV2.2 
corresponds with the increase of activation tau under steady-state deactivation but in both 
cases, the increases in the time it takes for CaV2.2 to activate is not consistent with 
increase Ba
2+
 influx. Thus, we would not expect an increase in activation taus to increase 
Ca
2+
 influx and subsequent neurotransmitter release within the in vivo system. This result 
is not consistent with increased Ca
2+
 via CaV2.2 resulting in increased neurotransmitter 
release. 
The effect of deltamethrin on 4α-PMA-treated CaV2.2 was a significant increase 
in ηactivation constants at -30 mV, -20 mV and -10 mV at 10 min post treatment.  At -30 mV 
the ηactivation rate constant was nearly two times greater than the ηactivation rate constant of 
DMSO. Under steady-state depolarization, activation taus remain unchanged in the 
presence of 4α-PMA + deltamethrin , so the rate increase we observed under voltage-
dependent activation was unexpected and contradictory to what we observed under 
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steady-state conditions especially considering previous reports of 4α-PMA being a non-
active form of PMA (Castagna et al., 1982; García-Ferreiro et al., 2001). The rate 
increase would indicate, within the in vivo system, that CaV2.2 would take longer to 
activate and that the amount of neurotransmitter that would eventually be released as a 
result of Ca
2+
 influx once the channel opened would be reduced.  
Under steady-state conditions, we observed that deltamethrin had no significant 
effect on the deactivation tau of unphosphorylated CaV2.2. We observed, likewise, that 
deltamethrin had almost no effect on voltage-dependent ηdeactivation, in the absence of PMA 
the exception being an increase in the length of time required for the channel to close at -
30 mV at 4 min post treatment. This means that within the in vivo system, the membrane 
would have to undergo a large depolarization in the presence of deltamethrin in order for 
there to be increased Ca
2+
 influx via unphosphorylated CaV2.2 followed by increased 
neurotransmitter release.  
The presence of deltamethrin on phosphorylated CaV2.2 under steady-state 
conditions increased deactivation tau allowing for an increase in Ba
2+ 
influx. There was 
no such increase, however, in voltage-dependent ηdeactivation rate constants.  This means 
that in the presence of deltamethrin the amount of Ba
2+
 entering the cell via 
phosphorylated CaV2.2 does not significantly differ from Ba
2+
 influx of our No 
Treatment. We propose that the difference between the effect of PMA + deltamethrin on 
steady-state deactivation taus versus voltage-dependent ηdeactivation may be due the multiple 
step depolarizations undergone that occur the Activation Test Protocol used to obtain 
ηdeactivation versus the single step depolarization of the Transient Test Protocol. As CaV2.2 
undergoes multiple step depolarizations, the channels that are opening at lower potentials 
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are inactivating and remain in their unwilling state during subsequent depolarization 
steps. The inactivation of these channels may be a mechanism by which the maximal 
effect of deltamethrin on phosphorylated CaV2.2 during voltage-dependent protocols was 
not observed 
The presence of 4α-PMA + deltamethrin had no significant effect on steady-state 
deactivation taus at either 4 or 10 min post treatment, but caused significant decreases in 
ηdeactivation rate constants at both time points compared to the DMSO control at 
depolarization steps ranging from -60 mV to -30 mV.  These decreases mean that the 
presence of deltamethrin on a 4α-PMA-treated channel causes the channel to close an 
average of 40%  faster than it would in the presence of DMSO at step depolarizations at 
or above -60 mV, and these faster rates reduce the amount of Ba
2+
 entering the via 
CaV2.2. This faster rate of closure would translate as less Ca
2+
 uptake and less 
neurotransmitter released, which does not cause the effects we observe in CS-syndrome.   
These results differ from the steady-state data in that, under steady-state conditions, the 
presence of 4α-PMA + deltamethrin had no significant effect on steady-state deactivation 
gating kinetics.  
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CHAPTER 5 
SUMMARY AND FUTURE DIRECTIONS 
 
Consistent with a previous study by Symington et al. (2005), we observed a 
significant decrease in steady-state peak current when unphosphorylated CaV2.2 was 
treated with deltamethrin. The decrease in steady-state peak current itself is inconsistent 
with in vivo data, in which deltamethrin increased CaV2.2 currents and subsequent 
neurotransmitter release (Table 13). We also observed a decrease in voltage-dependent 
peak current of unphosphorylated CaV2.2 in the presence of deltamethrin. Although this 
is consistent with work by Symington et al. (2005), it is not consistent with in vivo data in 
which the presence of deltamethrin causes an increase in Ca
2+
 influx and subsequent 
neurotransmitter release. When deltamethrin is added to PMA-activated, PKC-dependent 
phosphorylated CaV2.2, steady-state and voltage-dependent peak current is significantly 
increased, which is consistent with the in vivo data. Additionally, we observed an increase 
in steady-state deactivation taus which is consistent with increased Ca
2+
 influx and 
neurotransmitter release. Also, consistent with enhanced neurotransmitter release, 
voltage-dependent activation midpoint potentials (V50act) of phosphorylated CaV2.2 in the 
presence of deltamethrin underwent a hyperpolarizing shift. We have been able to 
confirm previous reports which show that deltamethrin causes an increase in both steady-
state and voltage-dependent peak current of phosphorylated CaV2.2, but we have also 
reported novel changes in the kinetic profile of CaV2.2 (increased deactivation taus and 
hyperpolarizing shift in the V50act) under the same conditions which support enhanced 
Ca
2+
 influx and subsequent neurotransmitter release.  
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Table 13. Summary of transient and voltage-dependent data endpoints of both 
unphosphorylated and phosphorylated CaV2.2 modified by deltamethrin. 
Endpoint
Consistent w/ 
Neurotransmitter 
Release?
Endpoint
Consistent w/ 
Neurotransmitter 
Release?
Peak Current 87.4 ± 5.1      
♦(-18)
No 180.6 ± 15.3         
♦(69) ■(107)
Yes
Activation tau 100.9 ± 4.2 No 101.3 ± 3.8 No
Inactivation tau 123.8 ± 10.7 No 58.8 ± 6.5               
♦(-53) ■(-52)
No
Deactivation tau 125.6 ± 13.9 No 186.5 ± 42.5           
♦*(79)
Yes
Peak Current -1.00 ± 0.04 No -1.46 ± 0.19                            
◊(47) ♦(70) 
■*(46)
Yes
V50act -1.83 ± 0.35 No -2.09 ± 0.29                
●(-56)
Yes
V50inact -25.73 ± 2.47 No -44.07 ± 3.45         
♦(-28) ■(-71)
No
Peak Current 72.6 ± 15.8        
♦(-29) 
No 185.8 ± 5.6              
♦(82) ■(156)
Yes
Activation tau 107.7 ± 4.3 No 123.6 ± 6.1       
♦(14) ■(15)
No
Inactivation tau 243.7 ± 40.8 No 92.8 ± 12.5            
■(-62)
No
Deactivation tau 129.6 ± 15.3 No 160.3 ± 17.2    
♦*(54)
Yes
Peak Current -0.87 ± 0.05 
◊(-12%)
No -1.08 ± 0.17 
♦(21%)
No
V50act -3.44 ± 0.69 No -3.04 ± 0.61              
●(-117)
Yes
V50inact -21.21 ± 2.16 No -44.69 ± 1.56           
♦(-63) ■(-111)
No
T
ra
n
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en
t
Unphosphorylated + ΔM Phosphorylated + ΔM
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t
4 min 
10 min 
T
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t
 
An open diamond (◊) indicates significant difference from No Treatment. A closed 
diamond (♦) indicates significant difference from DMSO. A square (■) indicates 
significant difference from deltamethrin.  A circle (●) indicates significant difference 
from PMA. The values in parentheses (n) are percent increases or decreases. Significance 
was calculated using Student’s T-test (P<0.05). Symbols followed by an asterisk (*) 
indicate that the significance level was P < 0.1. 
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Symington et al. (2005) reported a significant increase in steady-state inactivation 
taus of deltamethrin-treated unphosphorylated CaV2.2 expressed in Xenopus oocytes 
consistent with enhanced neurotransmitter release. PMA-activated PKC-dependent 
phosphorylation of CaV2.2 enhanced steady-state peak current, activation and 
deactivation taus but reduced steady-state inactivation taus (Table 13). We observed an 
increase in steady-state inactivation tau but the change was not significant. Likewise, 
when deltamethrin is added to the phosphorylated channel, inactivation tau is similarly 
decreased in a manner that is inconsistent with in vivo that data showed deltamethrin, 
enhances Ca
2+
 influx and neurotransmitter release. In the presence of deltamethrin, the 
V50act of T422E underwent a depolarizing shift that was not consistent with our data 
showing a hyperpolarizing shift in V50act of phosphorylated wild type CaV2.2 in the 
presence of deltamethrin (Symington et al., 2007a). This difference between the T422E 
mutant and our wild type CaV2.2 data indicates that the other phosphorylation sites on 
CaV2.2 may contribute to Ca
2+
 influx in a way other than peak current.  V50inact of 
phosphorylated CaV2.2 in the presence of deltamethrin also underwent a hyperpolarizing 
shift that was not consistent with increased Ba
2+
 (or Ca
2+
) influx and subsequent 
neurotransmitter release. Increases in ηactivation or ηdeactivation would have been consistent 
with enhanced neurotransmitter release, however, other than a significant increase in 
ηdeactivation at 10 min post treatment and 30 mV, we did not observe any large changes 
compared to the control (Table 14). It has been shown (Fang et al., 2006) that CaV2.2 has 
five PKC-dependent phosphorylation sites of which, when phosphorylated, four are 
agonistic to channel function (Thr422, Ser1757, Ser2108 and Ser2132) while the other 
(Ser425) is antagonistic to channel function. Clearly, the current data supports the 
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Table 14.  Summary of voltage-dependent ηactivation and ηdeactivation data endpoints of both 
unphosphorylated and phosphorylated CaV2.2modified by deltamethrin. 
 
Voltage (mV) Endpoint
Consistent w/ 
Neurotransmitter 
Release?
Endpoint
Consistent w/ 
Neurotransmitter 
Release?
-30 4.80 ± 0.36 No 4.75 ± 0.39 No
-20 3.90 ± 0.25 No 3.96 ± 0.29 No
-10 3.17 ± 0.17 No 3.30 ± 0.21 No
0 2.58 ± 0.12 No 2.75 ± 0.15 No
10 2.10 ± 0.09 No 2.30 ± 0.11 No
20 1.72 ± 0.08 No 1.92 ± 0.09 No
30 1.40 ± 0.08 
◊(10)
1.60 ± 0.07 No
-80 1.55 ± 0.12 No 1.82 ± 0.17 No
-70 1.8 ± 0.14 No 1.99 ± 0.14 No
-60 2.09 ± 0.16 No 2.19 ± 0.10 No
-50 2.43 ± 0.19 No 2.42 ± 0.09 No
-40 2.83 ± 0.22 No 2.68 ± 0.14 No
-30 3.29 ± 0.26 
♦(15)
Yes 2.98 ± 0.23 No
-30 5.42 ± 0.32 No 5.07 ± 0.53 No
-20 4.34 ± 0.21 No 5.19 ± 0.99          
♦(33)
No
-10 3.47 ± 0.13 No 4.11 ± 0.58        
♦(28)
No
0 2.78 ± 0.08 No 3.28 ± 0.3        
♦(20)
No
10 2.23 ± 0.06 No 2.64 ± 0.13             
♦(23) ■(18)
No
20 1.79 ± 0.06 No 2.14 ± 0.03           
♦(21) ■(20)
No
30 1.44 ± 0.06 No 1.75 ± 0.07          
♦(20) ■(22)
No
-80 1.52 ± 0.08 No 1.62 ± 0.17 No
-70 1.77 ± 0.1 No 1.89 ± 0.15 No
-60 2.06 ± 0.13 No 2.22 ± 0.14 No
-50 2.41 ± 0.17 No 2.61 ± 0.15 No
-40 2.81 ± 0.22 No 3.08 ± 0.21 No
-30 3.28 ± 0.28 No 3.65 ± 0.33 No
Unphosphorylated + ΔM Phosphorylated + ΔM
10 min
η a
ct
iv
at
io
n
η d
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ct
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at
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n
η d
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ct
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at
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n
η a
ct
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An open diamond (◊) indicates significant difference from No Treatment. A closed 
diamond (♦) indicates significant difference from DMSO. A square (■) indicates 
significant difference from deltamethrin. The values in parentheses (n) are percent 
increases or decreases. Significance was calculated using Student’s T-test (P<0.05).  
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contention that T422 is not independent of the other phosphorylation sites.   
The largest effect we observed on the unphosphorylated channel in the presence 
of deltamethrin was the decrease in both steady-state and voltage-dependent peak current. 
Since these results were in contrast to the effect of deltamethrin in vivo, they made clear 
the possibility that post-translational modification occurring on CaV2.2 within the in vivo 
system was either not present or not activated within the heterologous Xenopus oocyte 
expression system. When deltamethrin was applied to phosphorylated CaV2.2 expressed 
in Xenopus oocytes, we observed a reversal of deltamethrin inhibition of steady-state and 
voltage-dependent peak current. The largest of these changes was the enhancement of 
steady-state peak current, which remained significantly greater than did the DMSO or the 
deltamethrin treatments at 4 and 10 min post treatment, and was unlike voltage-
dependent peak current which decreased over 10 min.  The decrease in voltage-dependent 
peak current could be due to those channels sensitive to low levels of membrane 
depolarizations opening at those lower levels and being in the process of inactivating as 
the membrane undergoes increasing levels of step depolarization. We were able to 
replicate the steady-state peak current results of Symington et al. (2005) and Stea et al 
(1995) in regards to the action of deltamethrin and phosphorylation on CaV2.2 
respectively. When treating PKC-phosphorylated CaV2.2 with deltamethrin, we also 
observed similar increases in voltage-dependent peak current compared to the T422E 
experiments by Symington et al. (2007a) but we also obtained results that had yet to be 
described. 
We observed a novel increase in steady-state deactivation tau and a 
hyperpolarizing shift in V50act of PKC-phosphorylated CaV2.2 in the presence of 
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deltamethrin that was not evident when the T422E mutant (Symington et al., 2007a) was 
treated with deltamethrin. The slowing of deactivation occurred when phosphorylated 
CaV2.2 was treated with deltamethrin and this effect remained significant over 10 min.  
This effect was not observed by Symington et al. (2007a) because unlike their T422E 
mutant, our use of PMA-activated PKC-dependent phosphorylation had the potential to 
phosphorylate some or all the PKC sites on CaV2.2, with one or more of them having the 
potential to prolong steady-state deactivation tau. Lastly, we observed a significant shift 
in V50act of phosphorylated CaV2.2 in the presence of deltamethrin. This could mean that 
at least one of the PKC phosphorylation sites on CaV2.2 is responsible for making the 
channel more sensitive to membrane depolarization. Again, these novel results indicate 
that the simultaneous phosphorylation of multiple PKC-dependent phosphorylation sites 
creates CaV2.2 phosphoforms that yield unique kinetic profiles. 
Isoflurane, a volatile anesthetic, inhibits CaV2.2 steady-state and voltage-
dependent peak currents (Rajagopal et al., 2011) in much the same way deltamethrin 
decreased steady-state and voltage-dependent peak current. Using Ser/Thr→Ala site-
directed mutagenesis, Rajagopal et al. (2011) created constructs that eliminated either the 
stimulatory PKC-dependent phosphorylation site (Thr422, Ser1757, Ser2108 and S2132) 
or the inhibitory PKC phosphorylation sites (Ser425) to determine the effect of 
isofluorane currents. In the presence of isoflurane, modified CaV2.2 currents in which the 
stimulatory sites were eliminated and Ser425 was left unchanged, were significantly 
decreased compared to the wild type channel. A similar experiment using deltamethrin 
may yield a similar result since isoflurane and deltamethrin have similar effects on the 
wild type channel. Conversely, the elimination of only the inhibitory site Ser425 reversed 
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the isoflurane inhibition of CaV2.2 currents and again, treating the same mutant construct 
with deltamethrin may yield a similar response since the two compounds have similar 
effects on the wild type channel. The next steps to take to determine the extent to which 
the CaV2.2 stimulatory sites and the inhibitory site play a role in enhancement or 
inhibition of CaV2.2 currents via would be to use several mutant constructs of the CaV2.2 
to determine what effects the different phosphorylation states have on CaV2.2 currents 
when exposed to deltamethrin. Fang et al. (2006) used several mutant constructs to 
observe the effects of phosphorylation on CaV2.2. They observed wildly varying 
responses to peak current when different PKC-dependent phosphorylation sites were 
made “permanently phosphorylated” while others were left “permanently 
unphosphorylated”. Two of the major observations Fang et al. (2006) made was that 
residue Thr422 significantly increase peak current and residue Ser425 significantly 
reduced peak current.  The other three PKC phosphorylation sites were also stimulatory 
but their effects were not nearly as significant as that of Thr422. In our experiments we 
observed an enhancement of wild type CaV2.2 currents in the presence of deltamethrin 
beyond the enhancement of peak current.  Clearly phosphorylation of Thr422 is important 
in enhancing CaV2.2 currents, but if it were the only important site, we would not have 
observed changes in steady-state deactivation tau or V50act which both contribute to 
enhanced Ca
2+
 influx and subsequent neurotransmitter release. In order to determine what 
role each of the PKC phosphorylation sites play in kinetic profile of CaV2.2 in the 
presence of deltamethrin we will have to implement an exhaustive site-directed 
mutagenesis study similar to the one performed by Fang et al. (2006).  
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 APPENDIX 
COMPOUNDS USED IN THIS STUDY 
Deltmethrin
phorbol 12-myristate 13-acetate (PMA) 
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